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Abstract 
Lipid peroxidation (LP) proceeds by a free radical chain reaction mechanism in 
which molecular oxygen is incorporated into polyunsaturated fatty acids (PUFA) 
to yield lipid hydroperoxides (LOOH).  The ultimate end-products of LP are the 
production of α, β unsaturated aldehydes, such as acrolein, 4-hydroxy-2-nonenal 
(HNE) and malondialdehyde (MDA).  These aldehydes are very reactive and 
exhibit facile reactivity with various biomolecules, particularly proteins, resulting 
in the formation of fluorescent adducts that could be useful biological marker in 
diseases.  These fluorescent adducts typically emit light between 400 and 600 
nm when excited at wavelengths ranging from 300-400 nm.  Lysine residues are 
the major amino-acids that are predicated to react with aldehydes to yield 
fluorescent adducts.  LP has been implicated in several diseases such as 
atherosclerosis, Parkinson, Alzheimer, and diabetes.   
Water-soluble fluorescent species  (WSF) are fluorescent species that exhibited 
similar fluorescence characteristics for excitation and emission to those from 
aldehyde-modified proteins and amino-acids analogues.  WSF showed also 
direct correlation with age, so it suggested that its components could serve as a 
useful biomarker for in vivo LP. 
We determined that WSF was composed of two main components, a high 
molecular weight protein component and a low molecular weight non-protein 
component.  The non-protein component was unreactive towards proteins.  We 
were able to identify four major protein species in the protein component that 
contributed to the fluorescence.  These protein species were HSA, HST, Ig-G 
and carbonic anhydrase, with HSA and HST being the major species contributing 
to the overall fluorescence in the protein component.  The fluorophore was 
determined to be covalently bound to the protein component. 
Using CNBr digestion on isolated HSA and HST, we were able to determine 
multiple fluorophore binding sites within both proteins.  We determined by MALDI 
TOF/MS that there were indeed MW increases in HSA and HST after aldehyde 
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modification due to the fluorophores formation.  In vitro studies on HSA 
determined a change in the pI due to aldehyde modifications.  In vitro functional 
studies on HST suggested that there might be a loss of one the HST Fe binding 
sites due to aldehyde modification. 
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1.0 Background 
1.1 Lipid Peroxidation (LP) 
LP serves as a marker of cellular oxidative stress and has long been recognized 
to contribute to oxidative damage, as well as to inflammatory processes, 
ischemia and reperfusion injury, and chronic diseases as atherosclerosis and 
cancer [1, 2].  LP is a ubiquitous process that occurs in all organisms living under 
aerobic conditions.  While oxygen is essential to life, it can be potentially toxic to 
living organisms due to its participation in the formation of free radicals.  LP 
proceeds by a free radical chain reaction mechanism in which molecular oxygen 
is incorporated into polyunsaturated fatty acids (PUFA) to yield lipid 
hydroperoxides (LOOH). Lipid hydroperoxides have been shown to produce 
irreversible impairment of membrane fluidity and elasticity, which can lead to 
rupture of the cell, and these changes are likely to be particularly significant in 
long-lived and predominantly post-mitotic cells such as neurons.  Most of these 
processes generate superoxide anion radical (O2-•) and H2O [2, 3, 4]. 
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Fig 1  Model for the mechanism of initiation of LP [5] 
 
Although a number of compounds initiate LP through direct production of 
oxidizing radicals, further peroxidation occurs by secondary processes involving 
enzyme activation in which unsaturated lipids serve as substrates. 
The breakdown products of LP are also believed to contribute to the production 
of lipofuscin, a structurally heterogeneous yellowish brown granular pigment that 
accumulates with age.  Lipofuscin is a fluorescent material that accumulates 
within intracellular granules composed, in part, of protein and lipid in postmitotic 
cells of a variety of organisms as they age.  Although reports on the fluorescence 
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properties vary, this material typically emits light between 400 and 600 nm when 
excited at wavelengths ranging from 300 to 400 nm.  It has been proposed that  
lipofuscin is generated upon reaction of LP products with various cellular 
components [6, 7]. 
1.1.1 Significance of LP End-Products 
Ultimate end-products of LP include α, β unsaturated aldehydes.  Unlike reactive 
free radicals, aldehydes are rather long-lived and can therefore, diffuse from site 
of their origin (i.e. membranes) and reach and attack targets intracellularly or 
extracellularly, which are distant from the initial free radical event.  These 
aldehydes once formed or activated induce diverse aspects of severe cellular 
stress, including peroxide formation (oxidative stress), chromosomal aberrations, 
sister chromatid exchanges, point mutation and cell killing.  These aldehydes are 
active and exhibit facile reactivity with various biomolecules including proteins, 
DNA and phospholipids, generating stable products at the end of a series of LP 
reactions.  The protein-bound aldehyde is therefore considered to be a useful 
biological marker in studies of degenerative diseases.  The relative amount of 
adducts varies with the type of reactive aldehyde, and is largely determined by 
yield and reactivity of aldehydes and the stability of the adducts.  Examples of 
these aldehydes are malondialdehyde (MDA), acrolein, and 4-hydroxy-2-nonenal 
(HNE) [8, 9, 10]. 
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Fig 2 Structures of some example of LP derived aldehydes [8] 
1.1.2 Role of reactive aldehydes in diseases 
An important part of the pathogenesis of atherosclerosis has been implicated by 
oxidative modification of low-density lipoproteins (LDL).  Formation of LP 
products bound to proteins in the vascular lesions, such as atherosclerotic 
lesions, is a phenomenon common in most, if not all, types of vascular damage 
associated with oxidative stress.  The events in atherosclerosis are monocyte 
migration from the blood stream, differentiation into macrophages in situ, uptake 
of oxidized LDL by macrophage-scavenger receptors, transformation of lipid-
laden macrophage into foam cells, smooth muscle cell proliferation and 
transformation into foam cells, and thus accumulation of foam cells leading to 
fatty streaks and subsequent plaque formation.    Normal LDL binds to receptors 
on the surface of cells that require cholesterol and is internalized, releasing 
cholesterol.  The possibility that reactive aldehydes play a role in the 
pathogenesis of atherosclerosis is suggested by the facts that (i) the level of 
reactive aldehydes increases in plasma in relation of extensive aortic 
atherosclerosis, (ii) high concentrations of aldehydes can be generated during 
the oxidation of LDL phospholipids, and (iii) the structural and functional changes 
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associated with the in vivo oxidation of LDL can also be produced by direct 
interaction of LDL with aldehydes [8,11-13]. 
HNE levels are elevated in diseased Alzeimer’s disease (AD) brain regions 
compared to age-matched controls.  In addition, free HNE is elevated in 
cerebrospinal fluid from AD patients compared to AD patients.  Protein adduction 
of aldehydes such as HNE and acrolein creates new epitopes that can be 
detected by appropriate antibodies [14]. 
The presence of the glyoxal-lysine adduct (CML) has been demonstrated in 
various tissues from patients with diabetic nephropathy and chronic renal failure 
and in atherosclerotic lesions of arterial walls.  Quantification of the MG-derived 
lysine-lysine dimer (MOLD) in human serum proteins revealed a significant 
increase in diabetic samples compared with normal samples [16,17]. 
1.2 Biomolecules Modification by Aldehydes. 
1.2.1 Protein Modification 
Modification of proteins by α, β unsaturated aldehydes results in the formation of 
fluorescent proteins.  The adducts formed from the in vitro incubation of proteins 
with aldehydes typically emit light between 400 and 600 nm when excited at 
wavelengths ranging between 300 to 400 nm [18]. 
HNE is considered as the most toxic and reactive of the generated aldehydes.  It 
has a broad spectrum of biological toxicity including inhibition of DNA and protein 
synthesis, inactivation of several enzymes, and modulation of expression of 
several genes [19, 20].  It is an aliphatic α, β unsaturated aldehyde that alkylates 
cellular nucleophilic groups located in proteins, nucleic acids or 
aminophospholipids.  HNE is a multifunctional alkylating agent.  It possesses a 
C2-C3 double bond in conjugation with a C1 aldehyde.  This structure causes C3 
to be a strong electrophilic center, a property that is enhanced by the electron 
withdrawing C4 hydroxyl group.  Michael addition at the C3 carbon can occur by 
nucleophilic groups such as thiols, histidinyl side chains, the ε-amino group of 
lysines, and other primary amines.  The aldehyde functionality of HNE reacts with 
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the ε-amino group of lysine to form a Schiff base that can eventually lead to the 
formation of a 2-pentylpyrrole through an imine intermediate.  In vitro 
experiments on small molecules and peptides had shown that 2 lysine residues 
were needed to react with the aldehyde for fluorophore formation.  Although it is 
generally accepted that the fluorescence in HNE-treated proteins involves the 
modifications of lysine residues, the structure of the fluorophore has so far not 
been determined [20-25]. 
Acrolein is another type of reactive aldehyde produced from LP.  It is a strong 
electrophile and shows high reactivity with nuclphiles, such as the sulfhydryl 
group of cysteine, imidazole group of histidine, and amino group of lysine.   Its 
high reactivity makes acrolein a dangerous substance for the living cell.  Acrolein 
undergoes nucleophilic addition at the double bond (C---3) to form a secondary 
derivative with retention of the aldehyde group, resulting in the formation of the 
Michael addition-type-acrolein-amino acid adducts.  In vitro studies have 
identified the Nε-(3-formyl-3,4-dehydropiperidino) lysine (FDP-lysine) [18,19]. 
 
 
 
 
Fig 3 Scheme of proposed formation of Nα-acetyllysine-HNE fluorophore 
[24] 
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Fig 4 Fluorescence spectra of Nα-acetyllysine-HNE fluorophore showing 
excitation maxima at 360 nm and emission maxima at 430 nm [24] 
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Fig 5 Proposed structures of adducts formed from different aldehydes [8] 
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Fig 6 Structure of aminophospholipid adduct [27] 
1.2.2 Aminophospholipid Modification 
In vitro studies have shown that HNE can react with aminophospholipids.  A 
study conducted by Guichardant et al., demonstrated that HNE can react with the 
amino group of phosphatidylethanolamine (PE), yielding the same kind of 
products found in amino acid treatment, namely a Michael adduct that represents 
the main derivative and a Schiff-base which is partially converted to a pyrrole 
derivative [27-29]. 
 
1.2.3 DNA Modification. 
In vitro studies have been conducted to study the modification of DNA with 
acrolein.  It has been suggested that acrolein modification of DNA may contribute 
to spontaneous mutagenesis, thereby playing a potential role in aging and 
cancer.  Upon incubation of acrolein with DNA, acrolein primarily reacts with 2-
deoxyguanosine and forms the 1,N-2-propano-2-deoxygyanosine adduct [30]. 
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 Fig 7 Structure of DNA adducts formed as a result of acrolein incubation 
[30] 
1.3 Water-soluble Fluorescent Species 
In 1985, Tsuchida et al. found that there were fluorescent substances in the 
protein fraction of mouse and human sera.  These fluorescent substances which 
were called water-soluble fluorescent species (WSF), had fluorescence spectra 
with excitation maxima at 335-340 nm and emission maxima at 435-440 nm in 
mice, and excitation maxima were at 355-360 nm and emission maxima at 430-
435 nm, respectively for humans.  Tsuchida et al. noted that these WSFs had 
similar spectral characteristics to those reported with lipofuscin previously [31].   
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 Fig 8 Fluorescence excitation and emission spectra of WSF pigments 
found in protein fraction of mouse (A) and human (B) sera [31] 
 
The aim of their study was to develop a reliable method to extract WSF from 
serum, as they proposed WSF as a marker of in vivo LP.   
Tsuchida et al. developed an assay for the extraction of WSF from sera of mice 
and humans.  In their studies, they determined that WSF correlated with the 
induction of in vivo LP caused by carbon tetrachloride.  Carbon tetrachloride is 
considered a stimulative agent of LP in liver.  Data showed that fluorescence 
intensity significantly increased after the administration of carbon tetrachloride.  
In addition, the spectral properties of WSF from test mice showed characteristics 
similar to those of control mice.  These data indicated that the fluorescence 
responded to stimulation of in vivo LP, and it further supported the assumption 
 25
that WSF originally present in sera of control mice might be products resulting 
from in vivo LP [31]. 
Tsuchida et al. also conducted a study to compare the fluorescence intensity of 
WSF from sera of healthy subjects and subjects suffering from various diseases 
such as diabetes, hypertension, hyperlipidemia etc.  They noticed that the 
fluorescence intensity of WSF from patients with diabetes or hypertension was 
significantly higher than that from healthy subjects [31]. 
Seybert et al. conducted a study showing that WSF fluorescence appeared to 
increase with age in humans even in normal population [32]. 
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1.4 Human Serum Albumin (HSA) 
Human serum albumin (HSA) is the most abundant and multifunctional protein in 
serum.  It is the major protein component of blood plasma, occurring at 
concentration of ~ 0.6 mM.  It can also be found in bodily tissues and secretions 
[33]. 
1.4.1 Function 
The primary function of HSA is to transport fatty acids, but because of its 
versatile capacities and high concentration, it can assume a number of additional 
functions.  HSA carries around 0.1-2 mol of fatty acid per mol protein.  HSA helps 
to maintain colloidal osmotic blood pressure and contributes to bodily 
detoxification by binding poisonous metabolites such as bilirubin [34]. 
Albumin carries bilirubin, the breakdown product of heme, to the liver for 
conjugation with glucuronic acid and subsequent excretion.  Albumin has one 
very strong binding constant (~108 M-1) and two weaker binding constants for 
bilirubin (~106 M-1).  It has been observed clinically and in experimental systems 
that when the bilirubin to HSA ratio exceeds 1, bilirubin binds to membranes [34].   
  HSA has been shown to be an important reservoir of the biological regulator 
and neuromodulator, nitric oxide.  In clinical situations, HSA affinity for an 
amazing array of different drugs means that the protein can have a major effect 
on pharmacokinetics.  HSA is capable of binding an extraordinarily broad range 
of drugs, and much of the clinical and pharmaceutical interest in the protein 
derives from its effects on drug pharmacokinetics.  Many studies have shown 
that the presence of fatty acids has unpredictable effects on drug binding, 
resulting in both co-operative and competitive interactions [35, 36].   
1.4.2 Structure 
HSA is a heart-shaped, monomeric protein of 585 amino acids with molecular 
weight of 68, 500 daltons (Da).  The protein is 67 % α-helical and entirely devoid 
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of β-sheet.  HSA is organized into three homologous domains (labeled I-III) and 
each domain is comprised of two sub-domains (A and B), which share common 
structural elements.  A total of 17 disulfide bridges contribute towards HSA’s 
thermostability [37, 38]. 
Although it is now well established that HSA has multiple fatty acid binding sites 
of varying affinities, the precise number of binding sites is not known.  Although 
the binding of fatty acids to HSA has been studied for over 40 years, still clear 
understanding of these interactions is far from complete.  Current consensus 
seems to be that there are two or three high-affinity sites and at least three 
further sites of lower affinity.  The binding sites are distributed across the three 
homologous domains.  Bhattacharya et al. conducted a crystallographic study of 
five HSA-fatty acid complexes formed using saturated medium-chain and long-
chain fatty acids (C10:0, C12:0, C14:0, C16:0, and C18:0).  A total of seven 
binding sites that are occupied by all medium-chain and long-chain fatty acids 
have been identified, although medium-chain fatty acids are found to bind at 
additional sites on the protein, yielding a total of 11 distinct binding locations.  
The two principal drug-binding sites, in sub-domains IIA and IIIA, are observed to 
be occupied by fatty acids and one of them (in IIIA) appears to coincide with a 
high affinity long-chain fatty acid binding site [36, 39, 40]. 
In essence the three domains are each adapted differently for fatty acid binding 
and no two binding sites are alike in detail, although each comprises a 
hydrophobic pocket capped at one end with basic or polar side chains.  The 
architecture of fatty acid binding sites on HSA is quite distinct from that of 
intracellular lipid-binding proteins which accommodate long-chain fatty acids 
within a 10-strand anti-parallel β-barrel capped by a pair of short α-helices.  
However, both types of protein bind fatty acids within hydrophobic cavities and 
employ arginine or lysine residues, usually in combination with tyrosines or 
serines, in order to hydrogen bond the carboxylate moiety of the bound lipid [41-
43]. 
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 Fig 9 Structures of HSA complexed with five different fatty acids.  The 
protein secondary structure is shown schematically.  The A and B sub-
domains are depicted in dark and light shades, respectively.  Bound fatty 
acids are shown in space filling representations [35] 
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1.4.3 In vitro HSA Modification by LP End-Products 
Several in vitro studies had been conducted on HSA and bovine serum albumin 
(BSA), where protein was incubated with α, β unsaturated aldehydes such as E-
2-octenal, HNE etc.  Alaiz and Barragan conducted a study, where they 
incubated BSA with E-2-octenal to determine changes induced in BSA.  They 
observed that the incubation produced fluorescent BSA with excitation maximum 
at 350 nm and emission maximum at 440 nm.  Structural analysis of fluorescent 
adducts using lysine derivatives showed the formation of pyridinium derivatives 
as stable end-products.  They also performed amino acid analysis of modified 
BSA to compare with unmodified BSA.  They noticed that there was a 24.84% 
loss of lysine residues due to modification.  They also noticed high MW bands on 
SDS-PAGE suggesting that E-2-octenal was capable of cross-linking the BSA 
[44]. 
 
Fig 10 Chemical structure of quanternary pyridinium salts [44] 
 
Another study was conducted by Hidalgo and Zamora, where BSA was 
incubated with 4,5-epoxy-2-E-heptenal (EH).  4,5-epoxy-2-alkenals are another 
type of secondary products of LP.  They also noticed after the incubation that 
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there was the production of fluorescent BSA with an excitation maximum at 350 
nm and an emission maximum at 430 nm.  Upon amino acid analysis of modified 
BSA, there was a loss of lysine residues as compared with unmodified BSA.  By 
SDS-PAGE, they noticed that there was 5% increase in the percentage of protein 
dimers [45].   
 
1.5 Human Serum Transferrin (HST) 
Human serum transferrin (HST) is a glycoprotein with MW of ~80 kDa found in 
blood plasma.  In normal healthy humans, the concentration of HST falls in the 
range of 25-40 µM [46].   
1.5.1 Function. 
The main function of HST is the transport of iron in blood.  HST has two high-
affinity iron-binding sites (K = 1020 M-1 at pH 7.4).  The concentration of free Fe 
(III) in the presence of HST is less than 10-12 M and at this concentration, iron is 
unable to trigger damage via hydroxyl-radical formation.  Iron is transported from 
the intestine and the liver, via HST, to tissues that require iron for normal 
metabolism.  A large proportion of iron is directed to bone marrow, the site of 
hemoglobin synthesis [47, 48]. 
Typically only 30% of the iron binding sites of HST are occupied.  Thus, it retains 
sufficient excess binding capacity to ensure that it is never saturated, except in 
chronic iron overload disorders.  This is largely to ensure the 
compartmentalization and strict regulation of iron mobilization, which in the free 
form is toxic.  Among other roles, HST may also contribute to the defense against 
infections by depriving microorganisms of iron, which is required for their growth 
and reproduction [49]. 
 31
1.5.2 Structure 
HST is a single-chain, bilobal glycoprotein consisting of 679 amino acids with two 
identical oligosaccharide moieties attached by N-glycosidic linkages to 
asparagine side chains.  The two lobes are homologous, termed N and C lobes, 
each bearing a single iron-binding site.  The two lobes share ~40% sequence 
homology and are presumed to have arisen by a series of gene duplication and 
fusion events.  Each lobe is further divided into two domains connected by two 
antiparallel β-strands that act as a hinge.  In each lobe the iron binding site lies in 
this interdomain [50]. 
HST is considered as one of the iron-tyrosinate protein family, where their 
structural feature is the coordination of tyrosine to metal centers in proteins.  
Structural data for many different transferrins show that each ferric ion is directly 
coordinated to the side chains of two tyrosine residues, one histidine residue, 
one aspartic residue, and two oxygens from the synergistic carbonate anion 
which is anchored by an arginine residue.  For the N-lobe the ligands are D63, 
Y95, Y188 and H249.  For the C-lobe the ligands are D392, Y426, Y517 and 
H585.  There is an absolute requirement for the presence of a synergistic anion 
to obtain high-affinity iron binding.  In the absence of a suitable synergistic anion, 
the affinity of HST for iron is so low as not to compete successfully with hydrolytic 
polymerization and non-specific binding effects.  Iron binding leads to a large 
conformational change in the HST structure in which the subdomains in each 
lobe twist and come together to close the cleft over the metal [51-53]. 
1.5.3 Iron Binding to HST 
Iron binding and release from HST occurs in a pH-dependent manner.  Iron binds 
to the protein in serum (pH ~7.4) and is delivered to the cells by receptor-
mediated endocytosis.  The diferric HST-receptor complex is targeted to an 
acidic medium (pH ~5.6) where iron is released.  The receptor and apo-HST 
return to the cell surface, and apo-HST is released to take more iron and repeat 
the cycle. On average, one molecule of HST is believed to undergo 200 such 
 32
cycles before being degraded.  HST ability to bind iron reversibly is easily 
determined by spectral analysis, as iron binding leads to a visible absorbance 
maximum around 465 nm, resulting in a change in the protein solution from 
colorless to salmon pink [54, 55]. 
1.5.4 Release of Iron. 
In vitro studies had shown that the two lobes of HST display different iron release 
mechanisms.  The two binding sites are not kinetically equivalent toward iron 
release from HST.  The C-site has the highest affinity for iron and retains it in 
acidic media, whereas the N-site is considered more basic and does not retain 
iron in acidic media.  Therefore, the iron release from the N-site is faster than the 
release from C-site.  Experiments had also indicated that the release of iron from 
the C-site is completely unaffected by whether the N-lobe is open or closed, 
implying a lack of cooperativity between the lobes [56, 57].  
1.5.4.1 Release of Iron from N-Site. 
Extensive studies have established the significant role of a pair of lysines (K206 
and K296) in the release of iron from the N-lobe.  Structural studies of 
recombinant HST N-lobe indicated that these lysine residues (which reside in 
different domains) share a hydrogen bond when the two domains come together 
as a result of iron binding.  The distance between these two lysines is 3.1 Å.  In 
apo-HST, these two lysines are far apart (9.0 Å) as a result of cleft opening when 
the two domains pivot away from each other.  Mutagenesis studies had 
demonstrated that mutation of K206 effectively locks the N-lobe into a closed 
conformation at pH 7.4 and greatly reduces the rate of iron release at pH 5.6.  
Studies showed that the two opposing lysines serve as an active trigger that 
helps open the N-lobe.  Protonation at low pH causes the two lysines to repel 
each other resulting in the opening of the cleft and release of iron [58-61]. 
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1.5.4.2 Release of Iron from C-Site 
The C-lobe exhibits different iron release properties as compared to the N-lobe.  
This is mainly due to the absence of an equivalent pair of lysines in the C-lobe.  
Structural studies conducted by Dewan et al. suggested that a triad compromised 
of a lysine (K534), arginine (R632), and aspartic acid (D634) might serve as the 
pH sensitive motif in the C-lobe.  Dewan et al. suggested that lowering the pH 
would result in weakening or breaking of hydrogen bonds bridging the Arg and 
Lys residues.  The triad appears to serve as a trigger that helps to initiate iron 
release rather than as a lock that prevents it.  Each residue of this triad must play 
an active role in the process of iron-release from the C-lobe, since mutation of 
any of these residues to an alanine drastically slows chelator-mediated iron-
release [61-63]. 
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1.6 Statement of Research 
1. LP’s α, β unsaturated aldehyde end-products have been implicated in 
numerous diseases such as atherosclerosis, diabetes and other disease 
states.  Modifications of proteins by aldehydes produce fluorescent 
species.  WSF extracted from human serum showed similar fluorescence 
properties to those products detected with in vitro protein and amino-acid 
derivatives modifications by aldehydes.  The goal was to identify and 
characterize the components of WSF (fluorophore binding to components 
and fluorophore binding sites within the components), and to identify the 
major species contributing to the fluorescence? 
2. In vitro studies demonstrated that proteins when modified by aldehydes 
can undergo conformational and functional changes as a result of 
fluorophore formation accompanied with significant loss of lysine 
residues.  The goal was to determine by in vitro experiments on HSA and 
HST, the structural and functional changes such as MW, pI and function 
that may have occurred as a result of aldehyde modification. 
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2.0 Experimental Methods and Instrumentation 
The following chemicals and reagents were obtained from Sigma: N-ethyl-
morpholine (99%), EDTA, Tiron, ammonium persulfate (>98%), sodium azide, 
sodium citrate (tribasic), acrylamide/bis-acrylamide (30%), HSA (99%), apo-HST 
(>98%), holo-HST (98%), BSA, idoacetic acid (99%), CNBr and iodoacetamide. 
The following chemicals and reagents were purchased from Bio-Rad:  Tris, 
Coomassie brilliant blue R250, P-2 gel (fine), P-10, Tween, mercapoethanol and 
TEMED. 
The following chemicals and reagents were obtained from Fisher: potassium 
chloride, potassium phosphate (ACS), potassium ferricyanide and ferrous 
ammonium sulfate. 
The following gel resins were from Pharmacia Chemicals: Sephadex G-75, 
Sephadex G-100 and DEAE Sepharose. 
Trans-2-hexenal (98%) was from Aldrich and trypsin was from Promega.  All 
other chemical and reagents used were of the highest commercial purity. 
The instruments used were: HPLC was from Waters with the following 
components: 600 pump, 470 scanning fluorescence detector and 2487 dual 
absorbance detector.  The ESI-MS was from Waters equipped with ZMD 
quadrupole mass analyzer.  The spectrofluorometer was from Photon 
Technology International using Felix TM software for fluorescence intensity with 
xenon arc lamp.  UV-Vis spectra and readings were obtained with a Varian 
CARY 3-E with temperature controller.   
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2.1 Extraction and characterizations of WSF from human serum 
2.1.1 Extraction of WSF 
The extraction of WSF from human serum was performed following the 
procedure published by Tsuchida et al. [31].  To 100 µl of serum, 4 ml of 
ethanol/ether mixture (3:1, v/v) was added.  The mixture was vortexed vigorously 
for 30 seconds, followed by centrifugation at 3000 rpm for 10 minutes.  The 
supernatant was discarded and the resulting pellet was mixed with 4 ml 
ethanol/ether mixture.  The mixture was vortexed again for 30 seconds followed 
by centrifugation at 3000 rpm for 10 minutes.  After discarding the supernatant, 
the resulting pellet was dissolved in 200 µl DDH2O.  Fluorescence intensity of the 
WSF solution was measured with excitation at 350 nm and emission at 460 nm.  
Slit widths of the spectrofluorometer of both the excitation and emission 
monochromators were set at 5 nm (used in all experiments unless otherwise 
specified).  The fluorescence data were normalized using quinine (0.1 µg/ml) in 
0.05 M H2SO4 as a standard to read 100 relative fluorescence units. 
2.1.2 Attempted Chemical Reduction of WSF Extract 
WSF was extracted from serum following procedure 2.1.1.  WSF at a protein 
concentration of 10 mg/ml was treated with 0.75 M NaBH4 for 24 h at room 
temperature (RT).  Reduced WSF (2 ml) extract was passed through a Sephadex 
G-75 gel filtration column (2.2 cm x 93 cm).  The equilibrating buffer components 
were:  10 mM potassium monophosphate (KPi), 150 mM potassium chloride 
(KCl) and 0.02% sodium azide (NaN3), pH 7.0.  The buffer was prepared by 
dissolving the appropriate amounts of buffer components in DDH2O, and pH was 
adjusted to 7.0 by adding 1 M potassium hydroxide (KOH).  All experiments 
described that included the use of the Sephadex G-75 column, were performed 
with the same equilibrating buffer unless otherwise specified.  Four ml fractions 
were collected and elution profiles were monitored by fluorescence (ex 350 nm, 
em 460 nm).  Fluorescence units of WSF were measured before applying to the 
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column.  Collection and analysis of fractions from a control sample were the 
same as the reduced WSF sample mentioned above. 
 
2.2 Separation and Characterization of WSF’s Protein Component 
2.2.1 Gel Filtration Chromatography 
A volume of 1.5 ml of WSF solution was passed through a G-75 column, and 4 
ml fractions were collected.  Elution profiles were monitored by absorbance (280 
nm) and fluorescence (ex 350 nm and em 460 nm). 
2.2.2 SDS-PAGE Gels 
Samples were analyzed by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) using 7-20% separating gels and 4-5% stacking 
gels, as discrete percentages.  The SDS-PAGE gels were prepared and run 
following procedure by Laemmli et al.  The high molecular weight standards that 
were run with samples for 7%-10% discrete gels contained the following six 
proteins with their molecular weights (MWs):  myosin (200 kDa), β-glactosidase 
(116 kDa), phosphorylase B (97.4 kDa), serum albumin (66 kDa), ovalbumin (45 
kDa), and carbonic anhydrase (31 kDa).    For SDS-PAGE gels of 20% 
separating gels the standards contained the following proteins: phosphorylase b 
(97.6 kDa), serum albumin (66 kDa), ovalbumin (45 kDa), carbonic anhydrase 
(30 kDa), trypsin inhibitor (21.5 kDa), and lysozyme (14.4 kDa).  
Estimates of MWs of unknown proteins were determined graphically from a 
standard plot of mobility (mm) versus log MW of standard proteins.  Kodak 3D 
program was also used to calculate band intensities and areas for determination 
of % purity of proteins as well as MW calculations. 
2.2.3 Denaturation Experiments 
Fractions from peaks A and B from G-75 were pooled together and concentrated 
to 2 ml using ultrafiltration.  The membrane used for ultrafiltration is PM10, with a 
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MW cutoff of 10 kDa.  The pressure used was 40 psi and the membrane was 
kept at 4°C during operation.  A volume of 1 ml of a concentrated mixture of 
peaks A and B was incubated with 1 ml of 8 M urea for 1 h at RT.  A control 
sample of just concentrated peaks A and B was left for 1 h at RT (same 
experimental conditions as sample except for urea).  Solution of 8 M urea was 
prepared by dissolving the appropriate amount of urea in DDH2O.  A volume of 
1.5 ml of incubated mixtures of both control and sample were passed through 
Sephadex G-75, and 4 ml fractions were collected.  The elution profile was 
monitored by absorbance (280 nm) and fluorescence intensity (ex 350 nm and 
em 460 nm). 
2.2.4 Protein Concentration Determinations 
Protein concentrations present in peaks A and B from G-75 were determined by 
Bradford assay.  Coomassie Brilliant Blue G-250 dye was prepared by diluting 1 
part dye concentrate with 4 parts DDH2O, followed by filtration through Whatman 
#1 filter paper.  A standard curve of absorbance at 595 nm versus protein 
concentration (mg/ml) was determined using bovine serum albumin (BSA) as 
protein standard.  To determine concentration of unknown protein mixture, 20 µl 
of protein sample were mixed with 1 ml dye.  The protein-dye mixture was left to 
sit for 10 minutes at RT.  The solution’s absorbance was read at 595 nm.  
Concentration was determined from the standard curve. 
2.2.5 Isolation of 67 kDa Protein Present in Peak B from the 
Sephadex G-75 Column 
The major band in peak B had a MW of 67 kDa as determined by SDS-PAGE.  
To separate this band from the rest of the other protein bands in peak B, pooled 
fractions of peak B from G-75 were concentrated using ultrafiltration.  Two ml of 
concentrated peak B at concentration of 10-14 mg/ml was passed through G-75 
column.  The elution profile was monitored by absorbance at 280 nm and 
fluorescence (ex 350 nm, em 460 nm).  Purity of the 67 kDa band across the 
peak was monitored by SDS-PAGE (10% separating, 4% stacking). 
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2.2.6 Removal of HSA from other protein species present in peak A 
from the Sephadex G-75 Column 
One of the major bands in peak A had a MW of 68 kDa and this was confirmed to 
be HSA.  To purify HSA, which is the major protein from the rest of protein 
bands, pooled fractions of peak A were concentrated using ultrafiltration.  Three 
ml samples of concentrated peak A at protein concentration of 10-15 mg/ml were 
passed through a Blue Sepharose CL-6B affinity column (1.2 cm x 9.3 cm).  
Column was equilibrated with 0.05 M Tris/HCl, 0.1 M KCl, pH 7.0.  A step 
gradient was used to elute proteins from column.  The high ionic strength buffer 
was composed of 0.05 M Tris/HCl, 1.5 M KCl, pH 7.0.  Buffers were made by 
dissolving the appropriate amount of solid in water, and pH was adjusted by 1 M 
HCl to the desired pH.  Two ml fractions were collected and elution profile was 
monitored by absorbance (280 nm) and fluorescence (ex 350 nm, em 460 nm).  
The run-through peak and the eluting peaks were analyzed by SDS-PAGE (10% 
separating, 4% stacking). 
2.2.7 Western Blot for Confirmation of 80 kDa Protein 
A western blot was conducted on run-through from the affinity column to confirm 
presence of HST.  SDS-PAGE gels (10% separating, 4% stacking) were 
prepared and loaded with 8 µg of sample containing HST and prestained 
standards (MWs 203, 137, 79, 42.3 and 31.6 kDa).  The SDS-PAGE gel and the 
nitrocellulose membrane (0.45 µm) were equilibrated in the transfer buffer for 20 
minutes.  Transfer buffer was composed of 25 mM Tris, 192 mM glycine, 20% 
(v/v) methanol, pH 8.3.  After assembling the sandwich containing the gel, 
membrane and filter papers, transfer of proteins from gel to membrane was 
performed electrophoretically for 1h at 100 V.  After transfer, the membrane was 
incubated with the blocking buffer for 20 minutes with gentle shaking.  Blocking 
buffer was composed of 20 mM Tris, 500 mM NaCl, 1% nonfat dry milk (w/v), pH 
7.5.  After the 20 minutes incubation, fresh 20 ml blocking buffer and 20 µl of 
antitransferrin antibody were incubated with membrane for 1 h.  After the 1 h 
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incubation, membrane was washed three times with 15 ml of blocking buffer.  
Next 20 ml of fresh blocking buffer and 20 µl of horse-radish peroxidase (HRP)-
conjugated anti-goat IgG were incubated with membrane for 1 h.  After 
incubation membrane was washed twice with 15 ml buffer containing 20 mM Tris, 
500 mM NaCl, 0.05% Tween (v/v), pH 7.5.  Then membrane was washed once 
with 10 ml buffer containing 20 mM Tris, 500 mM NaCl, pH 7.5.  At the end, 10 
ml of color reagent was added to the membrane and incubated until colors were 
visible.  The color reagent was prepared by mixing 10 ml 4-chloronapthol with 6 
µl of 30% H2O2.  All buffers used in this experiment were prepared by dissolving 
the appropriate amount of solid in DDH2O and adjusting of pH by 1 M HCl.  
2.2.8 Isolation of HST 
Pooled fractions of run-through peak from the affinity column were concentrated 
by ultrafiltration.  Two ml samples at protein concentration of 2-6 mg/ml were 
passed through a DEAE-Sepharose column (2cm x 27cm).  Equilibrating buffer 
was composed of 10 mM Tris/HCl, pH 7.4.  Using a gradient mixer, a gradient of 
0-100 mM NaCl was used to elute HST from column.  Two ml fractions were 
collected and the elution profile was monitored by absorbance (280 nm) and 
fluorescence (ex 350 nm, em 460 nm).  Purity of HST was assessed by SDS-
PAGE gel (10% separating, 4% stacking).  A western blot was also performed to 
confirm, presence to HST. 
2.2.9 HSA and HST Aldehyde Modification 
The aldehydes used for modification were hex and 4-ONE.  An amount of 12 mg 
of desired protein was dissolved in 10 mM KPi, pH 7.4.  The concentrations of 
aldehydes used were 4 mM for the 4-ONE and 15 mM for the hex.  Then the 
aldehydes were mixed with the proteins and incubated at 37°C.  The time of 
incubations was 6 h for HST and 48 h for HSA.  The incubated mixtures were 
then dialyzed versus DDH2O for 48 h to remove excess unreacted aldehydes.  
Then the dialyzed mixtures were evaporated to dryness using a Speed Vac. 
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2.3 MALDI TOF/MS 
2.3.1 Proteins Identifications and Confirmations from SDS-PAGE 
Gel Protein Plugs using MALDI-TOF/MS 
Gel plugs from the desired protein band were cut from the SDS-PAGE gel.  Gel 
plugs were dehydrated for pre-trypsin digestion with the addition of 100 μl of 1:1 
(v/v) methanol/ 50 mM NH4CO3 followed by shaking for 30 min at RT.  The 
supernatant was removed by pipetting followed by another addition of 100 μl of 
1:1 (v/v) methanol / 50 mM NH4HCO3 followed by another shaking for 30 min at 
RT.  After supernatant removal, 50 μl of 100% acetonitrile (ACN) was added to 
the gel plugs followed by Speed Vac drying for 15 min.  The dried gel plugs were 
then incubated with 10 μl trypsin for 4 h at 45°C.  After the incubation, 7 μl of 
supernatant was pipetted to a 0.65 ml tube.  To the trypsin digested plugs, 60 μl 
of 1% TFA/ 50% ACN was added followed by shaking for 30 min at RT to extract 
proteins from gel plugs.  Tubes containing extracted protein solutions were then 
Speed Vac dried for 2 h at 45°C. 
The dried pellets were dissolved in 3 μl 0.3% TFA/ 50% ACN and mixed with 3 μl 
(1:1) of 10 mg/ml matrix dissolved in 800 μl 0.3% TFA/ 50% ACN.  The matrix 
used was α-cayno-4-hydroxycinnamic acid (CHCA).  The sample/matrix mixtures 
were spotted on a MALDI plate followed by MS analysis using the Applied 
Biosystems 4700 Proteomics Analyzer.  NCBlr human database search for 
protein matches was performed using the Applied Biosystems GPS Explorer 
software.  The report generated would have the MW, PI, protein score, C.I. % 
and accession number.  The protein score is a relative indication of the quality of 
the hit.  It is dependent on a number of factors, and usually the higher the score 
the higher the quality of the hit.  The minimum protein score that is trusted to a 
good protein hit is 60.     The C.I.% (confidence index) represents the % 
confidence of the program on the protein hit.  Higher C.I.% is coupled with high 
protein scores. 
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2.3.2 In vitro Structural Studies on Aldehyde Modified HSA and HST 
using MALDI TOF/MS 
Studies were conducted on a Voyager-DE PRO for the MALDI analysis.  
Aldehyde modified samples of HSA and HST was prepared as described in 
2.2.9.  Instrument conditions for sample analysis were as follows:  linear and 
positive mode, accelerating voltage = 25000 V, grid = 94%, guide wire = 0.1%, 
delay time 500 nsec, matrix = sinapinic acid.  Before all analyses, the instrument 
was calibrated with commercial HSA and apo-HST. 
2.4 Characterization Studies on HSA 
2.4.1 CNBr Digestion of Isolated HSA 
HSA was digested into seven peptide fragments using cyanogen bromide 
(CNBr).  CNBr is specific at cleaving at methionine residues within proteins.  
Since HSA has six methionine residues within its amino acid sequence, seven 
fragments were produced as a result by digestion with CNBr.  Since there are 17 
disulfide bonds, HSA was first reduced with dithiothreithol (DTT) followed by 
reaction with iodoacetic acid (IA).  Then the reduced and carboxymethylated 
HSA was digested with CNBr [65, 66].  The molecular weights and locations in 
protein sequence of the expected fragments are shown in Table1: 
 
Fragment Partial Sequence M.W. (Da) 
I 1-87 10 022 
II 88-123 4334 
III 124-298 20 704 
IV 299-329 3357 
V 330-446 13 902 
VI 447-548 11 941 
VII 549-585 4097 
Table 1 MW and sequence positions of CNBr fragments of HSA [66] 
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Fig 11 CNBr fragments of HSA separated by tricine gel electrophoresis with 
the assignment of MW to each respective band [66] 
 
Isolated HSA was digested with CNBr to yield seven peptide fragments, MW 
ranging from 3.4-20 kDa.  CNBr digestion of HSA was carried out following a 
procedure by Iadarola et al.  HSA at a concentration of 10 mg/ml was reduced 
under nitrogen for 3 h in a reduction medium containing 1 M Tris/HCl, 6 M 
guanidine chloride (GuHCl), and a 10 fold molar excess of dithiothreithol (DTT) 
over the disulfides bonds (SH) concentration, pH 8.0.  Iodoacetic acid (IA) (2-fold 
excess over total protein cysteines plus DTT concentrations) was added, and the 
mixture was maintained in the dark for 1 h.  Reaction was terminated by addition 
of 6 µl of 2-mercapoethanol.  Excess reagents were removed by dialysis versus 
DDH O and the resulting protein was lyophilized.  The lyophilized HSA pellet was 
dissolved in 2 ml solution of CNBr solid dissolved in 70% formic acid.  Amount of 
CNBr mixed with HSA was a 200 molar excess of CNBr over the methionine 
residues.  The CNBr/HSA mixture was incubated for 24 h under nitrogen at RT in 
dark.  At the end of the 24 h incubation, the mixture was diluted 20-fold with 
DDH O followed by lyophilization.  The lyophilized CNBr digested HSA pellet was 
dissolved in 2 ml 0.1% trifluoroacetic acid (TFA) for further analysis.  
Fragmentation of HSA was monitored by SDS-PAGE gels (20% separating, 5% 
stacking). 
2
2
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2.4.2 Separation of Peptide Fragments using Gel Filtration 
Chromatography 
CNBr fragments of HSA were separated using Ulrogel AcA 202 column gel 
filtration column (1.9 cm x 83 cm) with fractionation range of 1-20 kDa.  The 
column was equilibrated with 5% formic acid, 0.02% NaN3 mixture.  One ml 
samples at protein concentration of ~4 mg/ml were applied to the column.  Two 
ml fractions were collected and the elution profile was monitored by absorbance 
(220 nm) and fluorescence (ex 350 nm, em 460 nm). 
2.4.3 Separation of Peptide Fragments from CNBr-digested of 
Isolated HSA using HPLC 
The literature showed the fragments could be separated and resolved using 
HPLC.  The column used in the separation was a Vydac C18 column.  Two 
solvents were used for the elution of fragments:  A:  0.05% TFA, B: acetonitrile-2 
proponal (2:1 v/v) containing 0.05% TFA.  The HPLC C18 column was 
equilibrated with 80% A and 20% B.  The elution run was performed by running a 
gradient of 40% A and 60% B for 30 minutes at room temperature (RT) with a 
flow rate of 2 ml/min.  The absorbance was monitored at 220 nm [67, 68]. 
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CNBr digested HSA fragments were also separated by reversed-phase HPLC.  
Separation of fragments was achieved by the use of a Varian C18 column (5 µm, 
250 mm x 4.6 mm).  Elution of fragments was achieved by a gradient of two 
solvents:  0.05% TFA (solvent A), and acetonitrile-2 proponal (2:1, v/v) containing 
0.08% TFA (solvent B).  The column was equilibrated with 80% solvent A and 
20% solvent B.  For each run, 100 µl of peptide solution (corresponding to ~ 6 
nmol of protein) was injected through column.  The elution of peptide fragments 
was achieved by the use of 30 min gradient to final conditions of 40% solvent A 
and 60% solvent B at a flow rate of 0.5 ml/min [68].  All runs were performed at 
RT and elution profile was monitored by absorbance (220 nm) and fluorescence 
(ex 350 nm, em 460 nm).  
Fig 12 Separation of CNBr fragments of HSA using reversed-phase C18 
column HPLC.  Conditions are described in 2.3.3 [68] 
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2.4.4 Isoelectric Focusing (IEF) Experiments on HSA 
Two samples of HSA were prepared: one modified with hex and the other with 4-
ONE.  A control sample of 5 mg/ml HSA dissolved in 20 mM KPi, pH 7.4 was also 
prepared.  Volumes of 100 μl of the three samples were resuspended in lysis 
buffer.  The lysis buffer was composed of 7 M urea and 2 M thiourea.  The 
precipitates of the three samples were resuspended in 175 μl of rehydration 
buffer containing 25 mM DTT, 4% CHAPS and 0.2% ampholytes.  The 1st 
dimension was focusing in an 11 cm IPG strip (pH range 5-9) followed by the 2nd 
dimension, which was a 12% SDS-PAGE gel.  The stepwise run power 
conditions for the IEF experiments were as follows:  100 V for 60 min, 250 V for 
60 min, 500 V for 30 min (total 150 min).  
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2.5 Structural studies on HST 
2.5.1 CNBr Digestion of Isolated HST and Peptide Fragments 
Separation 
Apo-HST was digested with CNBr and peptide fragments were resolved using 
the Sephadex G-100 gel filtration column equilibrated with 5% formic acid 
separated the fragments produced.  Three peaks were resolved and the elution 
profile was monitored by absorbance intensity at 280 nm.  The peaks were 
assigned as CN-A, CN-B and CN-C, where CN-A contained four peptide 
fragments, CN-B contained two peptide fragments and CN-C contained only one 
peptide fragment [69]. 
Since HST has 19 disulfides bonds, CN-A and CN-B were reduced with 
mercaptoethanol and followed by carboxyamidomethylation using 
iodoacetamide.  The reduced and carboxyamidomethylated peak CN-A was 
passed through G-100 column [69, 70]. 
Fig 13 Separation of CNBr fragments of HST on Sephadex G-100.  Elution 
profile monitored at absorbance 280 nm [69] 
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Fig 14 Separation of reduced and carboxyamidomethylated CN-A peptides 
on Sephadex G-100.  The elution profile monitored at absorbance 280 nm 
from G-100 column [69]   
Fig 15 Separation of reduced and carboxyamidomethylated CN-B peptides 
on Sephadex G-50.  Elution profile monitored at absorbance 280 nm [69] 
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The four fragments were separated (fragments 1-4 from table 2).  The reduced 
and carboxyamidomethylated peak CN-B was passed through Sephadex G-50 
gel filtration column equilibrated with 5% formic acid.  Two peaks were resolved 
corresponding to fragments 5 and 6 from table 2.  The elution profile from G-50 
column was monitored by absorbance intensity at 280 nm52. 
Isolated HST at concentration of 10 mg/ml was incubated with 20 mg/ml CNBr 
dissolved in 70% formic acid for 24 h in dark at 25°C.  After 24 h incubation, the 
mixture was lyophilized [69].  The lyophilized CNBr digest containing the peptide 
fragments of M.W. ranging from 5-58 kDa, was dissolved in 5% formic acid 
followed by elution through a P-10 column (1.5 cm x 83 cm), a gel filtration 
column with fractionation range of 2-20 kDa.  Three ml fractions were collected 
and the elution profile was monitored by absorbance (at 280 nm) and 
fluorescence (ex 350 nm, em 460 nm).   
2.5.2 Reduction and Carboxyamidomethylation of Peak A of CNBr-
digested Isolated HST from P-10 Column 
Peak A was reduced and carboxyamidomethylated following the procedure of 
Sutton et al.  Lyophilized peak A at concentration of 10 mg/ml was dissolved in 
0.2 M Tris/HCl, 8 M urea, pH 8.6, followed by addition of 1% (v/v) 2-
mercaptoethanol.  The mixture was incubated at 25°C for 4 h, followed by 
addition of 30 mg of iodoacetamide per ml and incubated for another 30 min.  
Reaction was terminated by addition of excess 2-mercaptoethanol [69].  The 
peptide fragments were applied through a P-10 column equilibrated with 5% 
formic acid.  Three ml fractions were collected and elution profile was monitored 
by absorbance (at 280 nm) and fluorescence (ex 350 nm, em 460). 
2.5.3 Separation of CNBr-digested Isolated HST Peptide Fragments 
using HPLC 
CNBr digested HST fragments were also separated by reversed-phase HPLC.  
Separation of fragments was achieved by the use of Varian C18 column (5 µm, 
250 mm x 4.6 mm).  Elution of fragments was achieved by a gradient of these 
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two solvents:  0.05% TFA (solvent A), and acetonitrile (solvent B).  The column 
was equilibrated with 100% solvent A.  For each run, 100 µl of peptide solution 
(corresponding to ~ 15 nmol of protein) was injected through column.  Elution of 
peptide fragments was achieved by the use of 35 min gradient to final conditions 
of 40% solvent A and 60% solvent B at a flow rate of 0.5 ml/min.  All runs were 
performed at RT and elution profile was monitored by absorbance (280 nm) and 
fluorescence (ex 350 nm, em 460 nm).  
2.6 In vitro functional Studies on HST 
2.6.1 Protein Fluorescence Experiments 
Apo and diferric HST at concentrations 0.3 mM dissolved in 20 mM KPi, pH 7.5 
buffer, were incubated with 15 mM hex or 4 mM 4-ONE dissolved in the same 
buffer at 37°C.  Control samples of both apo and holo HST were incubated at 
37°C, without addition of hex or 4-ONE.  Aliquots were taken of samples and 
controls at 1 h intervals.  Each aliquot consisted of 50 µl of sample or control 
diluted to 2.5 ml with KPi buffer.  Then the aliquots were read for fluorescence 
units (ex 350 nm, em 460 nm), using quinine as standard.  Aliquots were also 
analyzed by SDS-PAGE gels (7.5% separating, 4% stacking). 
2.6.2 Iron Uptake by Apo and Aldehyde Modified HST (Titration 
Experiments) 
Fe(III)Cl3.6H2O was dissolved in 1.10 M trisodium citrate to give a final 
concentration of 15 mg/ml.  The solution (Fe (III)/citrate molar ratio, 0.05) was 
diluted 50-fold with H2O and stored at 4°C.  Apo-HST was dissolved to a 
concentration of 10 mg/ml in 0.1 M Tris/HCl, 25 mM Na2CO3 pH 8.0.  10 µl 
aliquots (each containing 10.8 nmol Fe) were added to apo-HST (5 mg; 62.5 
nmol) dissolved in 1 ml 0.1 M Tris/HCl, 25 mM Na2CO3 in 2 ml cuvette.  After 
each addition, the reaction mixture was mixed with Pasteur pipette for 15 
seconds, and the absorbance at 465 nm was measured after 1 min [55]. 
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2.6.3 Iron Uptake by Apo and Aldehyde Modified HST (Saturation 
Experiments) 
Apo-HST at concentration of 0.2 mM was dissolved in 1 ml 0.1 M HEPES, 25 
mM NaHCO3 pH 7.5.  The solution was mixed with 2 ml solution of 0.01 M 
ferrous ammonium sulfate dissolved in 0.01 M HCl.  After 24 h equilibration 
period to ensure maximum binding, the percent saturation was assayed 
spectrphotometrically, ε465 = 2500 M-1 cm-1/Fe.  Measured saturation levels were 
typically > 90% [54].  To produce hex and 4-ONE modified apo-HST, apo-HST at 
concentration 0.3 mM was incubated with 15 mM hex or 4 mM 4-ONE for 7 h at 
37°C.  After incubation, the mixture was dialyzed vs H2O to ensure removal of 
aldehydes.  The dialyzed protein sample was dried using Speed Vac.  The dried 
pellet was dissolved in one of the two buffers used for the kinetics experiments 
(mentioned below).  
2.6.4 Iron Kinetics of Release from Normal and Modified Diferric 
HST at pH 7.4 
Kinetics of iron release from HST samples at pH 7.4 was measured by 
monitoring the absorbance change at 480 nm for release of Fe to the chelator 
Tiron.  A circulating water bath maintained the temperature at 25°C during the 
experiment.  Final concentration, of 6 µM protein and 12 mM Tiron in a total 
volume of 2 ml in 0.1 M HEPES pH 7.4, were used for the kinetic assays [61].  
The curve resulting from a plot of absorbance vs time was fitted to a double-
exponential function using Origin software. 
2.6.5 Iron Kinetics of Release from Normal and Aldehyde Modified 
Diferric HST at pH 5.6 
Kinetics of iron release from HST samples at pH 5.6 was measured by 
monitoring the absorbance change at 470 nm for release of Fe from protein to 
the chelator EDTA.  Final concentration, of 6 µM protein and 4 mM EDTA in a 
total volume of 2 ml in 0.1 M MES pH 5.6, were used in the kinetic runs (at 
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temperature 25°C) [61].  Since the rate of release from N-lobe was too rapid to 
accurately measure under the conditions mentioned, the first two minutes of data 
(N–lobe) were omitted from the analysis, and the remaining data were fit using a 
single-exponential function using Origin software. 
2.7 Characterizations of peak C of WSF (the non-protein component). 
2.7.1 Concentrating Peak C 
Pooled fractions of peak C from the Sephadex G-75 column were passed 
through a P-2 gel filtration column (fractionation range 100-1800 Da).  P-2 
column (1.8 cm x 27.9 cm) was equilibrated with 100 mM N-ethyl-morpholine and 
0.02% NaN3, pH 7.4.  Three ml fractions were collected and the elution profile 
was monitored by fluorescence (ex 350 nm, em 460 nm).  Pooled fractions were 
concentrated and evaporated to dryness using the Speed Vac instrument.  The 
resulting pellet was dissolved in DDH2O for further experiments. 
2.7.2 MW Determination of Peak C using Electrospray Ionization 
(ESI) MS 
Concentrated peak C was suspended in 100% ACN, HCl mixture and 2 ml was 
injected into a Waters ESI/TOF MS for MW determinations.  Instrument 
conditions for the analysis were as follows:  positive mode, cone voltage = 30 V, 
ion energy = 0.2, source heater = 100, and desolvation temperature 100. 
2.7.3 Peak C reactivity 
To determine peak C reactivity towards proteins, 2 ml sample of pooled 
concentrated fractions from P-2 column 100 mM N-ethyl-morpholine and 0.02% 
NaN3, pH 7.4 were incubated with 5 mg/ml HSA (commercial) for 24 h at 37°C.  
A control sample of 5 mg/ml HSA was also prepared and incubated for 24 h at 
37°C.  HSA was dissolved in 20 mM KPi, pH 7.4.  Both control and experimental 
samples of HSA and peak C were passed through G-75.  Four ml fractions were 
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collected and elution profile was monitored by fluorescence (ex 350 nm, em 460 
nm). 
2.8 Serum Incubation Experiments 
Two ml samples of whole serum were incubated with hex (15 mM) and 4-ONE 
(4mM) for 24 h at 37°C.  The incubated samples were dialyzed vs DDH2O to 
remove excess aldehydes.   Extraction was performed on dialyzed samples to 
extract WSF following procedure mentioned in 1.1.  The two samples of WSF 
extracts dissolved in DDH2O of both aldehyde incubations were passed through 
G-75 column.  Four ml fractions were collected and elution profile was monitored 
by fluorescence (ex 350 nm, em 460 nm).  Fractions were also analyzed by SDS-
PAGE gels (10% separating, 4% stacking). 
2.9 Human subjects’ study 
WSF were extracted from serum of six different individuals using procedure 
mentioned in 1.1.  The extracts from the six subjects were passed through G-75 
column.  For each subject, four ml fractions were collected and elution profile 
was monitored by absorbance (280 nm) and fluorescence (ex 350 nm, em 460 
nm).  Peak areas were calculated by fitting peaks to nonlinear Gaussian fits 
using Origin Software. 
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3.0 Results 
3.1 Components of WSF Extracted from Human Serum 
3.1.1 Isolation of WSF Extract from Human Serum 
WSF was extracted from human serum according to the procedure by Tshcuida 
et al. (as described in the experimental section, followed by passage of extract 
through the Sephadex G-75 gel filtration column.  
Three fluorescence peaks and two absorbance peaks were detected from the 
Sephadex G-75 column elution profile.  The peaks were labeled peaks A, B and 
C, according to the fluorescence elution order.  
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Fig 16 Elution profile of WSF extract passed through the Sephadex G-75 
column, monitored by absorbance at 280 nm and fluorescence intensity at 
ex 350 nm and em 460 nm.  Arrow indicates the void volume of the column 
 55
  
Fig 17 Top: Excitation spectrum of WSF extract from the Sephadex G-75 
column.  Bottom: Emission spectrum of peak WSF extract 
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Fig 18 Top: Excitation spectrum of peak A from the Sephadex G-75 column.  
Bottom: Emission spectrum of peak A 
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Fig 19 Top: Excitation spectrum of peak B from the Sephadex G-75 column.  
Bottom: Emission spectrum of peak B. 
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 Fig 20 Top: Excitation spectrum of peak C from the Sephadex G-75 column.  
Bottom: Emission spectrum of peak C 
 
Peaks A and B eluted in the excluded volume and high MW volumes of the 
Sephadex G-75 column, while peak C eluted in the included volume and low MW 
region of the Sephadex G-75 column.  Peaks A and B exhibited strong 280 nm 
absorbance content which was not detectable in peak C.  This suggested that 
WSF consisted of 2 major components: first component was the protein 
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component composed of peaks A and B and a second non-protein component 
composed of peak C.  Peak C showed no protein content using BioRad assay.  
SDS-PAGE gel of peaks A and B showed multiple protein bands. 
3.1.2 Reduction of WSF Extract with NaBH4 
To detect if there would be an effect of reduction with NaBH4 on fluorescence 
properties of WSF components, WSF extract was incubated with NaBH4 as 
mentioned in experimental section.  Reduced and control samples of WSF were 
passed through a Sephadex G-75 column. 
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Fig 21 The elution profile of control and NaBH -reduced WSF passed 
through the Sephadex G-75 column monitored by fluorescence intensity at 
ex 350 nm and em 460 nm.  Arrow indicates the void volume of column 
4
 
Comparisons between fluorescence units of reduced WSF extract before and 
after elution through the Sephadex G-75 are illustrated in Table 2.  This was 
performed to track fluorescence units before and after passage through the 
 60
Sephadex G-75 column, and observe if fluorescence units would be the same or 
different. 
 
Passage through G-75 Fluorescence Units 
Before 18.5 
After 18.6 
Table 2 Fluorescence units calculated, as mentioned in experimental 
section, of NaBH4 reduced WSF before and after passage through the 
Sephadex G-75 column 
 
The elution profile showed that there was no difference between control and 
reduced WSF, suggesting that reduction had no effect of fluorescence properties 
of peaks A, B and C.  There was also no loss of fluorescence as reduced WSF 
was passed through the Sephadex G-75 column. 
3.1.3 Binding that exists between fluorophore and protein 
component of WSF 
The aim was to determine if the fluorophore(s) was (were) covalently or 
noncovalently bound to proteins present in the protein component of WSF.  
Concentrated pooled peaks A and B fractions from the Sephadex G-75 column 
were incubated with urea as described in the experimental section.  Control and 
urea-treated samples were passed through the Sephadex G-75 column. 
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Fig 22 The elution profile of concentrated peaks A and B sample incubated 
with 8 M urea for 1 h at 37°C and control samples eluted through the 
Sephadex G-75 column, monitored by fluorescence intensity at ex 350 and 
em 460 nm.  Arrow indicates void volume of column 
 
The elution profile from Fig 22 showed that control and urea-treated samples 
displayed identical elution profiles from Sephadex G-75 column.  The elution 
profiles suggest that the fluorophore(s) are covalently bound to the proteins in the 
protein component of WSF as all of the fluorescence came out in the excluded 
volume of the Sephadex G-75 column. 
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3.2 Characterization of the Protein Component of WSF 
3.2.1 Purification of the Major Fluorescent Species in Peak B from 
the Sephadex G-75 column 
Concentrated samples of peak B fractions were composed of three major protein 
bands, with MWs of 80, 67 and 51 kDa as determined by SDS-PAGE. 
 
Fig 23 SDS-PAGE image showing WSF extract before passage through the 
Sephadex G-75, and peaks A and B eluted from the Sephadex G-75 column 
 
The major protein at 67 kDa suggested that it could be human serum albumin 
(HSA).  HSA is the most abundant protein in serum and has a MW of 68 kDa.  To 
purify the 67 kDa band from the other species, concentrated peak B was passed 
through a second Sephadex G-75 column (Fig 24). 
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Fig 24 The fluorescence elution profile of concentrate peak B through the 
Sephadex G-75 monitored at ex 350 nm and em 460 nm.  Arrow shows the 
void volume of the column 
 
Purity of 67 kDa protein was monitored by SDS-PAGE gel and >98% purity was 
obtained as described in the experimental section. 
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 Fig 25 Emission spectrum of the isolated pure HSA. Insert: SDS-PAGE 
image of the pure isolated HAS 
 
The emission spectrum show similar charactertics to those reported in the 
literature, suggesting that similar fluorophores were present on isolated HSA [25]. 
 
3.2.2 Protein identification of 67 kDa protein using MALDI TOF/MS 
In order to verify the identity of the 67 kDa protein, MALDI TOF/MS was used 
coupled with peptide mapping fingerprinting (PMF) database search for protein 
identification.  The 68 kDa SDS-PAGE band gel plug was trypsin digested 
followed by analysis using MALDI TOF/MS (Fig 26).  The generated peptides 
were searched against the protein database (Fig 27) as described in the 
experimental section.  
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Fig 26 MALDI MS spectrum of trypsin digested 67 kDa band analyzed by 
4700 Proteomics Analyzer TOF/MS as described in the experimental 
section 
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Rank Protein Name Accession No. Protein MW Protein Protein Protein 
         PI Score C. I. % 
  Human Serum Albumin In A Complex With Myristic gi|4389275 65992.7 5.69 113 100 
 Acid And Tri-Iodobenzoic Acid 
 Peptide Information 
 Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence
 Modification 
 Seq. Seq. 
 927.4934 927.5151 0.0217 23 135 141 YLYEIAR  
 960.5624 960.5754 0.013 14 400 407 FQNALLVR  
 1074.5425 1074.579 0.0365 34 179 187 LDELRDEGK  
 1149.615 1149.6636 0.0486 42 39 48 LVNEVTEFAK  
 1226.6051 1226.623 0.0179 15 8 17 FKDLGEENFK  
 1311.7419 1311.7794 0.0375 29 335 345 HPDYSVVLLLR  
 1342.6346 1342.6931 0.0585 44 543 554 AVMDDFAAFVEK  
 1467.843 1467.8947 0.0517 35 334 345 RHPDYSVVLLLR  
 1600.7311 1600.7909 0.0598 37 387 399 QNCELFEQLGEYK  
 1623.7875 1623.8462 0.0587 36 321 333 DVFLGMFLYEYAR  
 1639.9376 1639.9863 0.0487 30 411 425 KVPQVSTPTLVEVSR  
 1742.894 1742.9626 0.0686 39 143 156 HPYFYAPELLFFAK  
 1853.9102 1853.952 0.0418 23 482 497 RPCFSALEVDETYVPK  
 1875.0156 1875.0869 0.0713 38 62 78 SLHTLFGDKLCTVATLR  
 1898.9951 1899.0638 0.0687 36 143 157 HPYFYAPELLFFAKR  
 2045.0952 2045.1669 0.0717 35 370 386 VFDEFKPLVEEPQNLIK  
 2650.2639 2650.3396 0.0757 29 112 133 LVRPEVDVMCTAFHDNEETFLK 
Fig 27 Peptide fragments mapping fingerprinting database search hit for 
the 67 kDa protein band 
 
MALDI TOF/MS confirm that the 67 kDa protein was HSA as we suggested 
previously.  The high protein score coupled with a 100% C.I. % confirmed HSA.  
This demonstrates that HSA was the major species in the WSF and the most 
abundant protein. 
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3.2.3 Separation of proteins in peak A from the Sephadex G-75 
column from HSA. 
Concentrated pools of peak A fractions were composed of at least six protein 
bands as determined by SDS-PAGE gel, with major bands with MWs of 80, 67, 
51, and 30 kDa (Fig 23). 
As the 67 kDa protein was identified to be HSA and it was the most abundant 
protein, we wanted to observe if the fluorescence was present only in HSA or 
there were other species that possessed the fluorescence.  To separate the HSA 
from the rest of the species, affinity chromatography was used.  Blue Sepharose 
CL-6B affinity column (with a high binding specificity for HSA) was used for the 
separation as described in the experimental section.   
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Fig 28 The elution profile of concentrate peak A proteins passed through 
the Blue Sepharose affinity column with 1 M NaCl step gradient, monitored 
by absorbance at 280 nm and fluorescence intensity at ex 350 and em 460 
nm.  Arrow indicates the beginning of the gradient  
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Effectiveness of HSA removal from other protein was monitored by SDS-PAGE 
gels, which shown that >95% of HSA was removed and separated from the rest 
of species (Fig 29). 
 
Fig 29 SDS image peak A before and after passage through the affinity 
column.  Only the run-through peak is shown 
 
The elution profile from Blue Sepharose affinity column also shown there was 
fluorescence in the run-through peak (A*) suggesting that there were proteins 
and species other than HSA that exhibit the anomalous fluorescence.  The run-
through peak was composed of three major bands of 80, 51 and 30 kDa 
respectively, as determined by SDS-PAGE gel.  
3.2.4 Protein Identification and isolation of the 80 kDa protein from 
peak A* from the affinity column 
A protein of 80 kDa MW suggested that it could be human serum transferrin 
(HST).  HST is one of the abundant proteins in serum and has a MW of 80 kDa.  
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To confirm the presence of HST, a western blot experiment was performed on 
peak A* to detect if HST is the 80 kDA protein (Fig 30).  
 
Fig 30 Western blot experiment confirming the presence of HST in peak A* 
from the affinity column.  Standard (Std) contained HST 
The western blot confirmed that the 80 kDa protein corresponds to HST.  The 
next step was to isolate HST from the other two proteins mainly the 51 and 30 
kDa proteins, and to observe whether the fluorescence is present in HST or 
whether the other proteins contribute most of the fluorescence. 
To isolate HST, a DEAE Sepharose ion-exchange column was used as 
described in the experimental section [69] (Fig 31). 
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Fig 31 The elution profile of peak A* passed through the DEAE Sepharose 
column with 0-100 mM NaCl gradient, monitored by absorbance at 280 nm 
and fluorescence intensity at ex 350 nm and em 460 nm. Arrow indicates 
the beginning of the gradient 
 
The elution profile showed that both the HST and the run-through (peak A1) 
peaks contained fluorescence.  Peak A1 contained 2 bands with MW of 55 and 
30 kDa as determined by SDS-PAGE gel (Fig 35).  The majority of the 
fluorescence was present in HST as opposed to the other two proteins.  This 
suggested that HSA and HST were the two main and major species of the WSF 
protein component.  Purity of isolated HST was determined to be > 98% pure as 
determined by SDS-PAGE gel. 
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The fluorescence emission spectrum of isolated HST showed similar 
characteristics to that of isolated HSA suggesting the same fluorophore maybe 
present in both proteins.  This was significant as this suggests that WSF protein’s 
component contained similar fluorophore as that of in vitro studies [25]. 
 
 
 
 
 
Fig 32 Emission spectrum of the pure isolated HST.  Insert: SDS-PAGE 
image of the pure isolated HST  
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Fig 33 MALDI MS spectrum of 80 kDa band analyzed by 4700 Proteomics 
Analyzer TOF/MS as described in the experimental section 
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Rank Protein Name Accession No. Protein MW Protein Protein Protein  
 PI Score C. I. %  
 1 transferrin protein [Homo sapiens] gi|4557871 76999.6 6.81 160 100 
 Peptide Information 
 Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence
 Modification 
 Seq. Seq. 
 827.4046 827.4145 0.0099 12 565 571 NPDPWAK  
 964.5322 964.5309 -0.0013 -1 601 609 APNHAVVTR  
 997.4771 997.4808 0.0037 4 62 69 ASYLDCIR 
 1000.4985 1000.5045 0.006 6 669 676 YLGEEYVK  
 1125.6196 1125.5979 -0.0217 -19 613 621 EACVHKILR 
 1195.5524 1195.5582 0.0058 5 123 132 DSGFQMNQLR  
 1211.5472 1211.5605 0.0133 11 123 132 DSGFQMNQLR 
 1273.6534 1273.6676 0.0142 11 226 236 HSTIFENLANK  
 1276.632 1276.6624 0.0304 24 300 310 EFQLFSSPHGK  
 1283.5691 1283.5856 0.0165 13 531 541 EGYYGYTGAFR  
 1323.7167 1323.6871 -0.0296 -22 316 327 DSAHGFLKVPPR  
 1364.7241 1364.715 -0.0091 -7 542 553 CLVEKGDVAFVK 
 1415.7198 1415.7311 0.0113 8 47 60 SVIPSDGPSVACVK 
 1478.7347 1478.7516 0.0169 11 332 343 MYLGYEYVTAIR  
 1491.759 1491.7677 0.0087 6 298 310 SKEFQLFSSPHGK  
 1494.7296 1494.7467 0.0171 11 332 343 MYLGYEYVTAIR 
 1521.7366 1521.7572 0.0206 14 372 384 LKCDEWSVNSVGK 
 1529.7528 1529.796 0.0432 28 588 600 KPVEEYANCHLAR  
 1531.6879 1531.7059 0.018 12 684 696 CSTSSLLEACTFR 
 1565.7992 1565.8234 0.0242 15 647 659 DLLFRDDTVCLAK1
 1577.6576 1577.6754 0.0178 11 495 508 FDEFFSEGCAPGSK 
 1586.7743 1586.7919 0.0176 11 588 600 KPVEEYANCHLAR 
 1593.8093 1593.8243 0.015 9 476 489 TAGWNIPMGLLYNK 
 1659.7828 1659.8014 0.0186 11 683 696 KCSTSSLLEACTFR 
 1705.7526 1705.762 0.0094 6 495 509 FDEFFSEGCAPGSKK    
 1817.8043 1817.8513 0.047 26 347 362 EGTCPEAPTDECKPVK   
 1881.8759 1881.8922 0.0163 9 237 251 ADRDQYELLCLDNTR 
 1952.9381 1952.9438 0.0057 3 572 587 NLNEKDYELLCLDGTR 
 2171.0952 2171.095 -0.0002 0 144 162 SAGWNIPIGLLYCDLPEPR 
 2201.0325 2201.0547 0.0222 10 344 362 NLREGTCPEAPTDECKPVK   
 2233.1248 2233.1138 -0.011 -5 216 236 DGAGDVAFVKHSTIFENLANK  
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 2549.2927 2549.2673 -0.0254 -10 252 273 KPVDEYKDCHLAQVPSHTVVAR 
Fig 34 Peptide fragments mapping fingerprinting database search hit for 
the 80 kDa protein band 
 
MALDI TOF/MS analysis further confirmed isolated HSA.  A gel plug of HST was 
trypsin digested and analyzed by 4700 MS as described in the experimental 
section.  Peptide mapping fingerprinting confirmed HST with a high protein score 
and a 100% C.I.% HST. 
 
51 
30 
 
 
 
 
 
 
 
 
 
Fig 35 SDS image of pass-through from the DEAE column, showing the 30 
and 51 kDa proteins 
3.2.5 Protein Identifications of the 2 protein from DEAE column 
(peak A1) 
To gain knowledge about the identities of the 2 protein bands present in peak A1 
from DEAE Sepharose column, a MALDI experiment was conducted again 
coupled with peptide mapping fingerprinting database search.  Gel plugs of the 2 
proteins (51 and 30 kDa Fig 35) were trypsin digested and analyzed by MALDI 
as described in the experimental section. 
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Fig 36 MALDI spectrum of trypsin-digested 51 kDa protein band analyzed 
by 4700 Proteomics Analyzer TOF/MS as described in the experimental 
section 
 
 Rank Protein Name Accession No. Protein MW Protein Protein Protein 
 PI Score C. I. % 
  IGG protein [Homo sapiens] gi|38382881 51491.6 7.51 78 99.836 
 Peptide Information 
 Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence
 Modification 
 Seq. Seq. 
 838.5032 838.5125 0.0093 11 350 357 ALPAPIEK  
 1186.6466 1186.6469 0.0003 0 145 156 GPSVFPLAPSSK  
 1286.6738 1286.6774 0.0036 3 368 378 EPQVYTLPPSR  
 1671.8085 1671.7833 -0.0252 -15 312 324 TKPREEQYNSTYR  
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 1677.8019 1677.8094 0.0075 4 298 311 FNWYVDGVEVHNAK  
 1808.0065 1808.0044 -0.0021 -1 325 340 VVSVLTVLHQDWLNGK  
 1872.9701 1872.9779 0.0078 4 368 383 EPQVYTLPPSRDELTK  
 1873.9218 1873.9512 0.0294 16 416 432 TTPPVLDSDGSFFLYSK  
 2544.1313 2544.1458 0.0145 6 394 415 GFYPSDIAVEWESNGQPENNYK  
Fig 37 Peptide fragments mapping fingerprinting database search hit for 
the 51 kDa protein band 
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Fig 38 MALDI MS spectrum of trypsin-digested 30 kDa protein band 
analyzed by 4700 Proteomics Analyzer TOF/MS as described in the 
experimental section 
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Rank Protein Name Accession No. Protein MW Protein Protein Protein 
 PI Score C. I. % 
Carbonic Anhydrase Ii (Carbonate Dehydratase, Hca Ii,gi|1065006 29097.9 6.63 42 0 
 Ca2) (E.C.4.2.1.1) Mutant With Gln 92 Replac 
 Peptide Information 
 Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence
 Modification 
 Seq. Seq. 
 1141.5286 1141.5642 0.0356 31 9 17 HNGPEHWHK  
 1346.7426 1346.7205 -0.0221 -16 76 88 AVLKGGPLDGTYR  
 1581.8171 1581.8246 0.0075 5 113 125 YAAELHLVHWNTK  
 1709.9121 1709.9331 0.021 12 112 125 KYAAELHLVHWNTK  
    2667.2949  2667.2065    -0.08 -33 89    111      LIEFHFHWGSLDGQGSEHTVDKK 
Fig 39 Peptide fragments mapping fingerprinting database search hit for 
the 30 kDa protein band 
 
The peptide mapping fingerprinting database search the 51 kDa protein identified 
Ig-G with a high protein score and C.I.%.  For the 31 kDa protein, the database 
identified carbonic anhydrase as the protein but with a low protein score and 0 
C.I.%.  This could be due to the fact that carbonic anhydrase was in low 
abundance and amount that are major factors influencing the score.  But the MW 
agreed with what was expected  according to SDS-PAGE gel and that is a valid 
parameter for confirming proteins. 
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3.3 Investigation of the nature of the non-protein WSF component (peak 
C from the Sephadex G-75 Column) 
3.3.1 Peak C Purification and Concentration 
Peak C was designated as the non-protein component of WSF as it was negative 
towards protein assays and absorbance spectrum did not show any 
characteristic spectrum of protein and peptides (absorbance at 220 nm and 280 
nm).  Peak C was purified using P-2 gel filtration column (Fig 39) and 
concentrated using Speed Vac as described in the experimental section. 
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Fig 40 The fluorescence elution of WSF extract passed through the P-2 
column, monitored at ex 350 nm and em 460 nm, as described in the 
experimental section.  Arrow shows the void volume of column 
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3.3.2 Molecular weight determination of peak C using ESI-MS 
 
Fig 41 ESI-MS spectrum of peak C 
 
The molecular weight of peak C was determined to be 381.5 Da using ESI-MS as 
described in the experimental section.  The 267.5 Da peak corresponded to the 
buffer components, mainly the moropholine buffer used for elution from the P-2 
column. 
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3.3.3 Peak C Reactivity 
The aim of this experiment was to determine if peak C was a reactive species 
capable of reacting with proteins to generate a covalent fluorophore.  Peak C 
was incubated for 24 h with commercial HSA at 37°C.  The incubated mixture 
was passed through a Sephadex G-75 column as described in the experimental 
section. 
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Fig 42 Incubated mixture of peak C and HSA and control HSA passed 
through the Sephadex G-75 column. The fluorescence elution profile 
monitored at ex 350 nm and em 460 nm as described in the experimental 
section.  Arrow shows the void volume of the column 
 
The elution profile from the Sephadex G-75 column showed that the incubated 
mixture of peak C and HSA eluted as two peaks.  The control HSA matched 
perfectly with the HSA sample.  The elution profile suggested that peak C was 
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not reactive with HSA, as fluorescence was detected in the included volume of 
the Sephadex G-75 column, where it elutes normally for peak C. 
3.4 Characterization of Isolated Proteins 
3.4.1 HSA 
3.4.1.1 CNBr Digestion of Isolated HSA and Peptide Fragments 
Separation 
The aim of the experiment was to CNBr digest isolated HSA and determine if 
there were a single or multiple fluorophore binding sites.  This analysis, in 
addition to identifying multiple sites, could also determine where approximately in 
the amino acid sequence the fluorophore(s) are located.  CNBr digestion of 
isolated HSA produced the expected seven fragments as produced in the 
literature Fig 43 [66].  
Separation of CNBr fragments of isolated HSA was achieved by using Ulrogel 
AcA gel filtration column as described in the experimental section. 
   
  
Fig 43  SDS-PAGE image of CNBr digested HSA peptide fragments 
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Fig 44 The elution profile of CNBr fragments of isolated HSA passed 
through the Ulrogel AcA gel filtration column, monitored by absorbance at 
280 and fluorescence intensity at ex 350 and em 460 nm.  Arrow shows the 
void volume of column 
 
Absorbance elution profile from Ulrogel AcA column of CNBr peptide fragments 
of isolated HSA showed that there were four peaks, labeled peaks 1, 2, 3 and 4 
Fig 44.  The fluorescence elution profile detected three peaks correlating with 
absorbance peaks 1, 3 and 4 Fig 44.  The elution profile suggested that there 
were, in fact multiple binding sites of fluorophore within HSA.  Peak 1 had the 
highest absorbance and fluorescence intensity and confirmed by SDS-PAGE to 
be the 20 kDa peptide Fig 45.  We conducted distance calculations and 
determination of lysine residues using computational programs (MOE) Table 3 in 
HSA which identified 4 lysine pairs on the 20 kDa peptide fragment with very 
close proximity that could result on fluorophore formation and that explained the 
high fluorescence intensity as compared to other peptide fragments peaks.  
Peaks 3 and 4 had similar absorbance and fluorescence intensity and they both 
suggested that those were composed of more than one peptide fragment. 
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Fig 45 SDS-PAGE image of CNBr digested HSA peptide fragment and the 
20 kDa peptide band of peak 1 from the Ulrogel AcA column. 
 
 
 
 
 
 
 
Residue 1 Residue 2 Distances (Å) Peptide 
Fragment 
132 133 2.72 III (20 kDa) 
132 155 2.95 III (20 kDa) 
270 272 4.91 III (20 kDa) 
277 282 5.72 III (20 kDa) 
409 410 2.8 IV (3.4 kDa) 
432 435 60.3 IV (3.4 kDa) 
520 521 2.76 I (9.4 kDa) 
530 532 4.42 I (9.4 kDa) 
532 534 5.61 I (9.4 kDa) 
553 556 5.30 VII (4.0 kDa) 
537 541 6.56 VII (4.0 kDa) 
Table 3 Distances calculated using MOE program of lysine pairs that are 
within close proximity of HSA as described in the experimental section. 
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In order to better identify the CNBr fragments of isolated HSA that contained the 
fluorescence, reverse-phase HPLC was used.  HPLC should offer better 
separation and resolution than Ultrogel gel filtration column, plus it was coupled 
with a fluorescence detector to detect simultaneously absorbance and 
fluorescence.  C18 column was used for the separation as described in the 
experimental section. 
 
Fig 46 Elution of CNBr fragments of isolated HSA from reverse phase 
HPLC.  Run conditions were described in the experimental section 
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Fig 47 The fluorescence and absorbance elution profiles of CNBr fragments 
of isolated HSA from reverse-phase HPLC.  Run conditions were described 
in the experimental section 
 
The elution profile from HPLC suggested also multiple binding sites of 
fluorophore within HSA.  The following peptides showed fluorescence: 20, 9.4, 
4.0 and 3.4 kDa.  HPLC elution profile also showed that there were multiple 
fluorophore binding sites.  The 20 kDa peptide fragment showed again the 
highest fluorescence intensity as compared to other fragments.   
The elution profiles from both theUlrogel AcA column and the HPLC reverse-
phase C18 column confirmed that there were multiple binding sites of fluorophore 
within HSA. 
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3.4.1.2  In vitro characterization studies by MALDI TOF/MS 
Experiments were conducted using MALDI TOF/MS conducted on commercial 
HSA and in vitro aldehyde-modified HSA to detect any differences in MW 
between modified versus unmodified protein.  The aldehydes used for the 
modification of HSA were 2-hexenal (hex) and 4-oxo-2-nonenal (4-ONE).  
Pollack’s work in our lab showed that incubation of HSA with aldehyde at 37°C 
resulted in the development of fluorescence over a period of 48 hours.  So, if 
there was fluorescence development over time due to fluorophore formation, 
then a shift in MW of modified samples compared to control should occur and 
MALDI TOF/MS should be able to detect it. 
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Fig 48 MALDI MS spectrum of commercial HSA 
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Fig 49 MALDI MS spectrum of 4-ONE modified HSA 
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Fig 50 MALDI MS spectrum of hex modified HSA 
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 Sample Observed MW Difference Aldehyde 
Molecules 
Reacting 
HSA (control) 66363 -  
4-ONE modified 
HSA 
69357 2994 19 
Hex modified 
HSA 
69670 3307 34 
Table 4   Summary of MALDI TOF/MS experiments of HSA and aldehyde 
modified HSA (hex and 4-ONE) 
 
MALDI experiments confirmed the hypothesis that there was a MW increase in 
HSA due to modification.  Data had shown also that the number of hex molecules 
reacting to form the fluorophore(s) was higher than 4-ONE molecules.  This could 
be attributed to the fact that the concentration of hex used for the modification 
experiments (15 mM) was much higher than that of 4-ONE (4 mM), or it might 
reflect different steric constraints on the number of sites modified. 
3.4.1.3 In vitro Structural Characterizations using Isoelectric Focusing 
(IEF) Experiments 
The aim of this experiment was to detect any changes in the pI of HSA (5.69) 
due to aldehyde modification.  Aldehydes used were hex and 4-ONE as 
described in the experimental section.  Experiments in sec 3.4.1.2 showed that 
there was significant MW shift of aldehyde modified HSA versus a control 
unmodified HSA.  This meant that there was fluorophore formation and therefore, 
presumptive loss of lysine residues due to fluorophore formation.  If a significant 
number of lysine residues were lost due to modification then a change in pI 
should be observed with a shift towards the acidic side, concomitant with the loss 
of basic amino acids residues. 
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     Basic side                                                                 Acidic side 
 
Fig 51 IEF image of control HSA sample on a  IPG strip of pH range 5-8 
    Basic side                                                                    Acidic side 
 
Fig 52 IEF image of hex-modified HSA on a IPG strip with pH     range5-8 
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  Basic side                                                                      Acidic side 
 
Fig 53 IEF image of 4-ONE-modified HSA on a IPG strip with pH range 5-8 
 
IEF experimental results showed that there was a pI shift towards the acidic side 
for hex and 4-ONE modified HSA samples as compared to control unmodified 
HSA.  4-ONE sample showed more pI change than hex sample.  HSA isoforms 
were not that clear as the control sample as the isoforms are not clearly 
separated suggesting that there might be some crosslinking occurring between 
some isoforms. 
3.4.2 HST 
3.4.2.1 CNBr Digestion of Isolated HST Peptide Fragments Separation 
The aim of the experiment was to CNBr digest isolated  
HST and determine if there was one or multiple fluorophore binding sites.  
Isolated HST was digested with CNBr as described in the experimental section.  
Then CNBr digested isolated HST was passed through a P-10 gel filtration 
column.  The elution profile from P-10 column is shown in Fig 54. 
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Fig 54 The elution profile of CNBr-digested isolated HST passed through 
the P-10 column, monitored by absorbance at 280 nm and fluorescence 
intensity at ex 350 nm and em 460 nm.  Arrow shows the void volume of the 
gel 
 
Three peaks were detected by absorbance at 280 nm, labeled peaks A, B and C 
according to their elution order from column.  The fluorescence elution profile 
showed only one peak corresponding to absorbance peak A.  Peak A consisted 
of four peptide fragments of MW ranging from 7-27 kDa Fig 55.  Peak B 
consisted of two fragments of MWs 3 and 9 kDa.  Peak C contained only 1 
fragment with M.W. 5.8 kDa.   
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Fig 55 SDS-PAGE image of peak A of CNBr digested HST from the P-10 
column 
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Fig 56 The elution profile of reduced and carboxyamidomethylated peak A 
of CNBr-digested isolated HST through the P-10 column, monitored by 
absorbance at 280 nm and fluorescence intensity at ex 350 nm and em 460 
nm.  Arrow shows the void volume of the column 
 
To separate the four CNBr peptide fragments present in the fluorescent peak A, 
the peptide mixture was reduced and carboxyamidomethylated, then passed 
through a P-10 column as described in the experimental section.  
The elution profile from P-10 column showed two absorbance peaks, labeled 
peaks 1 and 2.  Fluorescence elution profile showed also 2 peaks correlating with 
absorbance peaks 1 and 2. 
The absorbance and fluorescence elution profile from P-10 column suggested 
multiple fluorophore binding sites within HST.  The four CNBr were not resolved 
using P-10 but the 2 peaks suggested that they each contained 2 peptide 
fragments.   
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In order to achieve better separation of CNBr isolated HST peptide fragments, 
reverse-phase HPLC was used.  This was a pilot experiment as there is no 
published procedure for separation of CNBr HST peptide fragments using HPLC.  
The advantage was that a better separation, resolution and using less peptide 
amounts could be attained using HPLC.  A C18 column was used for the 
separation as described in the experimental section. 
 
Fig 57 The elution profile of CNBr fragments of isolated HST from reverse-
phase HPLC.  Run conditions were described in the experimental section 
 
We were only successful on separating peaks A and B of CNBr digested isolated 
HST.  Attempts to separate the reduced and carboxyamidomethylated peak A 
peptide fragments were not successful. 
 97
3.4.2.2 In vitro characterizations studies using MALDI TOF/MS 
Experiments were conducted using MALDI TOF/MS conducted on commercial 
apo-HST and in vitro aldehyde-modified HST to detect any differences in MW 
shifts between modified versus unmodified samples.  The aldehydes used for the 
modification of HSA were hex and 4-ONE.   These experiments were conducted 
in parallel to those performed on HSA where significant MW shifts were observed 
due to modification.  Shifts in MW in aldehyde modified samples compared to 
control unmodified protein samples would corroborate that fluorophore formation 
had resulted from covalent adducts. 
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Fig 58 MALDI MS spectrum of commercial apo-HST 
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Fig 59 MALDI MS spectrum of 4-ONE modified apo-HST 
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Fig 60 MALDI MS spectrum of hex-modified apo-HST 
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 Sample Observed MW Difference Aldehyde 
molecules 
reacting 
HST (control) 78302 -  
4-ONE modified 80178 1876 12 
Hex modified 81732 3430 35 
Table 5 Summary of MALDI TOF/MS experiments on control and  aldehydes 
modified apo-HST 
 
MALDI experiments showed that there were significant MW shifts of aldehyde 
modified samples as compared to control unmodified apo-HST.  This confirmed 
that fluorophore formation led to shifts in MW of HST as it happened on HSA.  As 
in the case with HSA, the number of hex molecules reacting was higher again 
than 4-ONE molecules as this could be due to the higher hex concentration used 
for modification (15 mM) as apposed to 4-ONE concentration (4 mM), or it might 
reflect different steric constraints on the number of sites modified. 
3.5 In Vitro Fluorescent Development Studies on HST. 
In vitro studies were conducted on commercial apo and diferric HST to determine 
if there would be fluorescence development over time due to aldehyde 
modification.  Pollack’s work in our lab had demonstrated that there was 
fluorescence development of HSA over time upon incubation with aldehydes.  
This experiment was conducted to determine if similar pattern of fluorescence 
development over time would be detected. 
Apo and diferric HST were incubated for 24 h at 37°C with hex and 4-ONE, and 
time points were taken and fluorescence values were normalized using quinine 
as a standard as described in the experimental section.  Both apo and diferric 
forms were incubated with the aldehydes, to determine if either form would be 
more susceptible to aldehyde modification.   
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Fig 61 Fluorescence development time points plot of hex-modified apo and 
diferric HST 
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Fig 62 Fluorescence development time point plot of 4-ONE modified apo 
and diferric HST 
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 Fig 63 SDS-PAGE image of hex and 4-ONE modified apo-HST versus 
unmodified apo-HST 
 
Results showed rapid increase in fluorescence over time in aldehyde modified 
protein samples compared to control unmodified apo-HST, which displayed 
essentially no change.  Both aldehyde modified forms showed fluorescence 
development with time, but the apo-form showed a more pronounced 
fluorescence increase.  4-ONE modified forms of HST displayed higher 
fluorescence development as compared to hex modified forms of HST.  With 
both hex and 4-ONE modified HST, the apo form showed higher fluorescence 
development and increase compared to diferric HST. 
SDS-PAGE showed formation of high MW species for both hex and 4-ONE 
modified sample compared to the control sample, suggesting formation of 
crosslinked species as a result of aldehyde modification. 
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3.6 In Vitro Functional Studies on HST 
3.6.1 Iron Uptake 
The aim of this experiment was to subject apo-HST to aldehyde modification and 
determine if modification had an effect on the ability of apo-HST to bind Fe.  This 
was significant, as it would illustrate if aldehyde modification would have an effect 
on the function of apo-HST, which is the binding and transport of Fe. 
Iron uptake experiments were conducted by titration of aldehyde (hex and 4-
ONE) modified apo-HST with Fe (III)-citrate.  The titration was monitored by 
absorbance at 465 nm, and control and aldehyde (hex and 4-0NE) modified apo-
HST samples were analyzed as described in the experimental section.   
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Fig 64 Plot of Fe uptake titration experiment of control and 4-ONE-modified 
apo-HST samples as described in the experimental section.  Insert: 
Equivalence point determination using Origin software 
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Fig 65 Plot of Fe uptake titration experiments of control and hex modified 
apo-HST sample as described in the experimental section.  Insert: 
Equivalence point determination using Origin software 
 
Iron uptake experiments results showed that there were significant differences 
between the control and the aldehyde modified samples.  Both aldehyde 
modified samples showed decrease to iron binding as compared to control 
samples.  Equivalence points of the control samples showed a molar ratio of 
2.24, reflecting of the two binding sites of apo-HST.  The hex and 4-ONE 
modified apo-HST equivalence points showed molar ratios of 0.73 and 1.38 
respectively.   This suggested that there could be a loss of one of the binding 
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sites.  The other possibly that there was a decrease of iron binding on both sites 
due to aldehyde modification. 
3.6.2 Fe Kinetics of Release from Diferric HST 
To further investigate the apparent loss of binding sites of apo-HST due to 
aldehyde modification, in vitro kinetic of Fe release experiments were conducted 
measuring the rate of dissociation of Fe.  The hypothesis was that if there was a 
loss of a binding site, it might be the N-site as opposed to the C-site.  This was 
due to the fact that the N-site function depended on the action of two lysine 
residues for the uptake and release of Fe from HST, as mentioned in sec 1, thus 
making the N-site potentially more susceptible.  Kinetics of Fe release were 
conducted at pH 7.4 and 5.6, which were the pHs for iron uptake and release 
respectively as described in the experimental section.  
 
3.6.2.1 Fe Kinetics of Release from Commercial Diferric HST 
Commercial diferric-HST was used to optimize the kinetic experimental 
conditions and to observe if calculated rate constants were comparable with 
literature rate constant values.   
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Fig 66 Origin fit of kinetic of diferric-HST at pH 7.4 using Tiron as chelator 
and absorbance monitored at 480 nm 
 
Runs KN (x10-3) (min-1) KC (x10-3) (min-1) 
Literature 32.3 ± 1.4 8.5 ± 0.6 
Experimental 31 ± 7.8 4.7 ± 3.8 
Table 6 Calculated rate constants compared with literature values of 
kinetics of iron release of commercial diferric iron at pH 7.4 [61] 
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Fig 67 Origin fit of kinetics of diferric-HST at pH 5.6 using EDTA as chelator 
and absorbance monitored at 470 nm 
 
Runs KC (x10-3) (min-1) 
Literature  24 ± 0.8 
Experimental 23 ± 0.73 
Table 7 Calculated rate constants compared with literature values of 
kinetics of iron release of commercial diferric iron at pH 5.6 [61] 
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The calculated rate constants for pH 7.4 and pH 5.6 were very comparable with 
the literature rate constant values.  This suggested that the kinetic experiments 
were optimized and would yield reliable rate constants. 
3.6.2.2 Effect of Aldehyde Modification on Fe Kinetics of Release from 
Commercial Diferric HST 
Commercial diferric-HST was incubated with hex, and the kinetics of iron release 
were determined on control and hex-modified samples at pH 7.4 and 5.6, as 
described in the experimental section.  
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Fig 68 Origin fit of Fe kinetic of release of control diferric-HST using Tiron 
as chelator and absorbance monitored at 470 nm at pH 7.4 
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Fig 69 Origin fit of kinetic of hexenal modified diferric-HST using Tiron as 
chelator and absorbance monitored at 480 nm at pH 7.4 
 
Sample KN (x10-3) (min-1) KC (x10-3) (min-1) 
Control 35 ± 6.4 6.4 ± 3.4 
Hex modified 45 ± 10.1 5.4 ± 2.3 
Table 8 Comparison of calculated rate constants from Origin fits of kinetics 
of control and hex modified diferric HST at pH 7.4 
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Fig 70 Origin fit of kinetic of Fe release from control diferric HST using 
EDTA as chelator and absorbance monitored at 470 nm at pH 5.6 
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Fig 71 Origin fit of kinetic of Fe release from hex-modified diferric HST 
using EDTA as chelator and absorbance monitored at 470 nm at pH 5.6 
 
Sample KC (x10-3) (min-1) 
Control 31 ± 1.1 
Hex modified 21 ± 1.2 
Table 9 Comparison of calculated rate constants from Origin fits between 
control and hexenal modified HST at pH 5.6 
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At pH 7.4, there was no significant change or minimal change in rate constants at 
both The N and C-sites of the control and hex modified sample of commercial 
diferric HST.  At pH 5.6, there was a decrease in C-site rate constant hex 
modified sample as compared to the control sample of diferric HST.   
3.6.2.3 Saturation Experiment 
 The aim of this experiment was to modify apo-HST with aldehydes (hex and 4-
ONE) followed by saturation with Fe to determine the effect of modification on 
uptake and release of Fe.  If there was a loss of one of the binding sites of apo-
HST due to aldehyde modification, then uptake experiments followed by 
saturation with Fe, would result in the saturation of only one binding site and this 
should be reflected in the kinetics of Fe release experiments. 
Apo-HST was incubated with aldehydes (hex and 4-ONE) followed by saturation 
with ferrous ammonium sulfate as described in the experimental section.  A 
control sample was also prepared with only apo-HST and run through the same 
experimental conditions as the modified sample.  Fe release kinetics were 
determined on both control and modified diferric HST samples.   
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Fig 72 Origin fit of Fe kinetics of release of control saturated apo-HST using 
Tiron as chelator and absorbance monitored at 480 nm at pH 7.4 
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Fig 73 Origin fit of Fe kinetics of release of hex modified saturated apo-HST 
using Tiron as chelator and absorbance monitored at 480 nm at pH 7.4 
 
Sample KN (x10-3) (min-1) KC (x10-3) (min-1) 
Control 120 ± 24 2.4 ± 0.23 
Hex modified n/a 2.3 ± 0.53 
Table 10 Comparison of calculated rate constants of control and hex 
modified saturated apo-HST at pH 7.4 
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For pH 7.4, there was a clear difference between the control and hex modified 
diferric HST.  The control had the clear biphasic kinetics and displaying the 
release from the two binding sites.  On the other hand, the hex modified 
saturated diferric HST clearly displayed a monophasic kinetics suggesting that 
there maybe a loss of a binding site.  Calculations of rate constants showed that 
the calculated rate constant was for the C-site rate constant. 
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Fig 74 Origin fit of Fe kinetic of control saturated apo-HST using EDTA as 
chelator and absorbance monitored at 470 nm at pH 5.6 
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Fig 75 Origin fit of Fe kinetics of release of hex-modified saturated apo-HST 
using EDTA as chelator and absorbance monitored at 470 nm at pH 5.6 
 
Runs KC (x10-3) (min-1) 
Control 26 ± 5 
Sample 46 ± 4.1 
Table 11 Comparison of calculated rate constants from control and hex-
modified saturated apo-HST samples kinetics at pH 5.6 
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Comparing rate constants between control and hex-modified saturated apo-HST 
samples, the results showed there were minimal changes in the rate constant of 
site C in pH 5.6.  
An analogous series of kinetic experiments were repeated using 4-ONE 
modification of apo-HST, followed by saturation and kinetics of Fe release 
experiments as described in the experimental section. 
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Fig 76 Origin fit of Fe kinetics of release of 4-ONE modified saturated apo-
HST using Tiron as chelator and absorbance monitored at 480 nm at pH 7.4 
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Sample KN (x10-3) (min-1) KC (x10-3) (min-1) 
Control 120 ± 24 2.4 ± 0.23 
4-ONE modified n/a 7.1 ± 3.5 
Table 12 Comparison of calculated rate constants of control and 4-ONE 
modified saturated apo-HST at pH 7.4 
 
At pH 7.4, there was a difference between the control and 4-ONE modified 
diferric HST kinetics.  The control displayed biphasic kinetics while the 4-ONE 
modified displayed close to monophasic kinetics.  This suggested that there was 
loss of Fe binding at the N-site due to 4-ONE modification.  The calculated rate 
constants were comparable to the rate constants of the C-site.  The data was 
consistent with data of hex modified kinetics. 
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Fig 77 Origin fit of Fe kinetic of 4-ONE modified saturated apo-HST using 
EDTA as chelator and absorbance monitored at 470 nm at pH 5.6 
 
Runs KC (x10-3) (min-1) 
Control 26 ± 5 
Sample 3.2 ± 6 
Table 13 Comparison of calculated rate constants from control and 4-ONE 
modified saturated apo-HST samples kinetics at pH 5.6 
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At pH 5.6, there was significant difference between rate constants of control and 
4-ONE modified diferric sample of the C-site.   
3.6.2.4  Titration Experiment 
 The aim of the experiment was to titrate Fe into aldehyde-modified (hex and 4-
ONE) apo-HST followed by kinetic of release experiments to observe differences 
in calculated rate constants and to confirm results obtained from the saturation 
experiments.  These were experiments also to give insights if there was a loss of 
a binding site due to aldehyde modification.  Control and aldehyde-modified (hex 
and 4-ONE) apo-HST samples were titrated with Fe as described in the 
experimental section, and kinetics of release were determined on titrated control 
and aldehyde modified diferric HST.   
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Fig 78 Origin fit of Fe kinetics of release of control titrated apo-HST using 
Trion as chelator and absorbance monitored at 480 nm at pH 7.4 
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Fig 79 Origin fit of Fe kinetics of release of hex-modified titrated apo-HST 
run using Tiron as chelator and absorbance monitored at 480 nm at pH 7.4 
 
Sample KN (x10-3)) (min-1) KC (x10-3) (min-1) 
Control 101 ± 2.8 9.6 ± 0.57 
Hex modified n/a 2.5 ± 0.61 
Table 14 Comparison of calculated rate constants of kinetics from control 
and hex-modified titrated apo-HST samples at pH 7.4 
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At pH 7.4, there were differences between the control and hex modified diferric 
HST kinetics.  The control displayed the biphasic kinetics as compared to the 
monophasic kinetics of the hex modified diferric sample.  The calculated rate 
constant was comparable to those of the control C-site rate constant.  There was 
a 3-4 fold decrease in rate constants of the hex modified as compared to the 
control diferric HST. 
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Fig 80 Origin fit of Fe kinetics of release of control titrated apo-HST using 
EDTA as chelator and absorbance monitored at 470 nm at pH 5.6 
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Fig 81 Origin fit of Fe kinetics of release of hex-modified titrated apo-HST 
using EDTA as chelator and absorbance monitored at 470 nm at pH 5.6 
 
Sample KC (x10-3) (min-1) 
Control 23 ± 0.71 
Hex modified 26 ± 6 
Table 15 Comparison of calculated rate constants of control and hex-
modified titrated samples from kinetics at pH 5.6 
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Kinetics of Fe release at pH 5.6 showed comparable rate constants of the control 
and the hex modified diferric HST. 
Analogous experiments were conducted using 4-ONE as the modifying aldehyde 
followed by Fe titration and kinetics of release experiments as described in the 
experimental section. 
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Fig 82 Origin fit of Fe kinetics of release run of 4-ONE modified titrated apo-
HST using Tiron as chelator and absorbance monitored at 480 nm at pH 7.4 
Sample KN (x10-3)) (min-1) KC (x10-3) (min-1) 
Control 101 ± 2.8 9.6 ± 0.57 
4-ONE n/a 3.1 ± 0.89 
Table 16 Comparison of calculated rate constants of kinetics from control 
and 4-ONE modified titrated apo-HST samples at pH 7.4 
 
At pH 7.4, there was a difference between the control and 4-ONE modified 
kinetics of diferric HST.  The control displayed the biphasic kinetics while the 4-
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ONE modified displayed essentially monophasic kinetics.  Rate constant for the 
C-site showed approximately a 3-fold decrease due to modification. 
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Fig 83 Origin fit of Fe kinetics of release of 4-ONE modified titrated apo-
HST using EDTA as chelator and absorbance monitored at 470 nm at pH 5.6 
Sample KC (x10-3) (min-1) 
Control 23 ± 0.71 
4-ONE modified 13 ± 9 
Table 17 Comparison of calculated rate constants of control and hex-
modified titrated samples from kinetics at pH 5.6 
 
At pH 5.6, there was an approximate 2-fold decrease in the rate of C-site Fe 
release for the 4-ONE modified HST. 
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3.7  Serum Incubation Experiments 
The first aim of this experiment was to incubate whole serum with aldehydes (hex 
and 4-ONE) to determine if there would be differential changes in fluorescence 
intensities of the various WSF protein components.  The second aim was to try to 
detect if there would be evidence for protein-protein crosslinking.  Serum was 
incubated with aldehydes (hex and 4-ONE) for 24 h at 37°C, followed by 
extraction of the WSF and elution of extract through Sephadex G-75 column as 
described in the experimental section.  A control sample containing only serum 
was also prepared and eluted through the same experimental conditions as the 
aldehyde-modified samples.   
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Fig 84 Fluorescence elution profile of hex modified WSF extract passed 
through the Sephadex G-75 column, monitored by fluorescence intensity at 
ex 350 nm and em 460 nm.  Arrow shown the void volume of the column 
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 Fig 85 SDS-PAGE image of fractions of hex modified peaks A’ and B’ and 
control peak A, eluted from the Sephadex G-75 column 
The elution profile from the Sephadex G-75 column (Fig 81) showed almost a 3-
fold increase of fluorescence intensity of peaks A and B as compared to peaks A 
and B of the control sample.  The SDS-PAGE gel showed that there was 
formation of higher MW species possibly trimers of HSA (67 kDa band), as the 
high MW species showed a MW of about 190 kDa.  Peak B did not show any 
appearance of high MW species as compared to peak A. 
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Fig 86 The elution profile of 4-ONE modified extract passed through the 
Sephadex G-75 column, monitored by fluorescence intensity at ex 350 nm 
and em 460 nm.  Arrow shown void volume of the column 
 
The 4-ONE elution profile from the Sephadex G-75 column showed almost a 24-
fold fluorescence increase of peak A, and 20-fold fluorescence increase of peak 
B, as compared to the control unmodified peaks A  and B sample.  The 4-ONE 
elution profile showed a 9-fold fluorescence increase for peak A and a 10-fold 
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fluorescence increase of peak B, as compared peaks A and B from the hex 
elution profile. 
 
3.7 Subject Study 
The aim was to conduct a pilot study on serum samples from six different elderly 
subjects to observe if there would be variations of the component peaks of WSF 
extract between them.  WSF’s extract of the six subjects were passed through 
Sephadex G-75 column, and the elution profile was monitored by fluorescence 
and absorbance, and Origin program was used for the calculations of peak areas 
for peaks A and B as described in the experimental section.   
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Fig 87 Representative example of an Origin fit of one of the subjects 
Sephadex G-75 column fluorescence elution profile where peak areas of 
peaks A and B were calculated 
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Fig 88 Comparison of the six subjects based on peak areas percentages of 
peaks A and B 
 
The bar graph of the results from the study shows significant variations between 
the different individual serum samples in the composition of peaks A and B. 
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4.0 Discussion 
4.1 Separation and Characterization of WSF Extract Components 
WSF was extracted from human serum following procedure published by 
Tsuchida et al [31].  SDS-PAGE gel showed that WSF extract had multiple 
protein bands present with major bands at 80, 67, 51 and 30 kDa (Fig 23).  The 
presence of proteins in the WSF extract suggested that they might be 
contributors to the WSF, consistent with the literature that LP α, β unsaturated 
aldehydes end-products could react with proteins, resulting in the formation of 
fluorescent adducts.  These fluorophores with suggestions from the literature 
could induce structural and functional changes on the proteins that they react 
with [10, 18, 21]. 
Fluorescence excitation and emission spectra of extract showed an excitation 
maximum at 350 nm and emission maximum at 460 nm, which agreed with 
literature values [23, 24, 26] (Fig 17).  The observed excitation and emission 
wavelengths of extract were also in agreement of literature values of in vitro 
experiments of proteins and small amino acid analogues incubated with α, β 
unsaturated aldehydes such as HNE, hex, octenal, and 4-ONE.  These 
aldehydes are end-products from LP process, and they are very reactive towards 
biomolecules such as proteins.  Literature in vitro experiments showed that there 
was development of fluorescence on proteins as a result of incubation of 
proteins, due to modification of certain amino acids residues with aldehydes, 
particularly lysine residues [23, 26].  Fluorescence developed due to formation of 
adducts as a result of a reaction between aldehydes and amino acid residues of 
proteins.  This led us to believe that the WSF extracted from human serum was 
in fact a byproduct or marker of in vivo LP.   
The next question was, what were the different components or contributors to 
WSF?  To separate the different components of WSF, extract was eluted through 
a Sephadex G-75 gel filtration column as described in the experimental section.  
The fluorescence elution profile of WSF extract from Sephadex G-75 column 
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showed three major peaks, labeled peaks A, B and C, according to their elution 
order (Fig 16).  The absorbance elution profile at 280 nm identified two peaks 
coinciding with fluorescent peaks A and B (Fig 16).  Peaks A and B eluted in the 
high molecular weight region of column while peak C eluted in the low molecular 
weight (included) region of column.  The fluorescent and absorbance elution 
profiles suggested that WSF was made up of two main components: a high 
molecular weight protein-containing component (peaks A and B) and a low 
molecular weight non-protein component (peak C).  Excitation and emission 
fluorescent spectra of the WSF components were consistent with what was 
reported in the literature (Figs 16-20) [23, 24, 26]. 
4.1.1 Characterization of Peak C 
Peak C was determined to be non-protein species as it did not show any 
characteristic absorbance at 280 and 220 (data not shown) nm, which are the 
two main absorptions corresponding to the aromatic residues in proteins and to 
peptides, respectively.  Peak C was also negative towards Bio-Rad protein 
assay.  Peak C also eluted consistently through the different runs of WSF extract 
through Sephadex G-75 column, suggesting that it was an actual component of 
the WSF.  This suggested that peak C was the non-protein, low molecular 
component of WSF.    Fluorescence spectra of peak C exhibited an excitation at 
350 nm and emission at 460 nm, similar to the literature values for the 
fluorophore formation and similar to the high molecular species, suggesting that 
the same fluorophore was present in peak C species [23, 24, 26]. 
To gain a better understanding of the nature of peak C species, several 
experiments were conducted.  The first experiment was to try to determine the 
MW of the peak C species as this might give an insight of the identity of the 
species.  The P-2 gel filtration column was used to collect fractions of peak C, 
followed by Speed Vac of samples to concentrate the fractions (Fig 40).  To 
determine the mass of peak C species, ESI/MS was used.  The ESI/MS 
spectrum of peak C showed two major peaks at 267.5 Da and 381.5 Da (Fig 41).  
The 267.5 Da was consistent with the MW of morpholine buffer components 
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used for the elution through the P-2 column.  This suggested that morpholine 
buffer wasn’t completely removed by the Speed Vac prior to the ESI-MS 
analysis. 
On the other hand, peak 381.5 Da suggested that it was the MW of the peak C 
species.  The 381.5 Da peak appeared consistently on multiple analysis by ESI-
MS.  The MW did not give us any insights of what it could be.  One possibility 
that it could be a degraded peptide fragment of one of the modified serum 
proteins that might contain the fluorophore.  The other possibility that it could be 
a phosopholipid molecule modified by LP’s aldehyde, as literature showed that 
such modification could occur.  One other possibility that could be an amine-
containing compound that might be modified and contained the fluorophore. 
To gain a better understanding about the potential reactivity of peak C species 
towards biomolecules particulary proteins, concentrated peak C was incubated 
with commercial HSA.  Control HSA and HSA-peak C sample, were eluted 
through the Sephadex G-75 column.  The elution profile from Sephadex G-75 
column showed that peak C species was not a reactive species towards proteins 
(Fig 42).  This was demonstrated as peak C eluted at its normal low MW region 
and HSA eluted in the high MW region (as well as the control HSA sample) of the 
Sephadex G-75 column.  This demonstrates that peak C was an unreactive 
species towards proteins.  This raised the possibility it could be a cleaved 
fragment of a modified aminophospholipid that contained the fluorophore.  Or it 
could be a degraded fragment that contained the fluorophore.  Or it could be an 
end-product fluorophore of a low molecular weight amine-containing serum 
component.  
4.1.2 Reduction Experiments on WSF 
The literature suggested that formation of adducts within proteins due to 
modification with aldehydes could proceed through Schiff-base or Michael 
addition reactions or both [23-26].  Schiff-base reactions are reversible reactions, 
so if WSF was formed from a Schiff-base reaction intermediate without further 
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reaction then it would be a reversible intermediate and its fluorescence should be 
altered if reduced.  To address this Schiff base question, WSF extract was 
reduced with NaBH4 followed by eluting through the Sephadex G-75 column.     
The fluorescence elution profile from the Sephadex G-75 column did not show 
differences from control samples (Fig 21).  Calculated normalized fluorescence 
units of reduced sample showed no difference before and after passage through 
Sephadex G-75 column (Table 2).  This suggested no loss of fluorescence after 
reduction and eluting through the Sephadex G-75 column.  
The elution profile from the Sephadex G-75 column showed that there was no 
effect of reduction on the fluorescent properties of WSF’s components, 
consistent with the absence of a Schiff-base adduct.  This finding is consistent 
with a fluorophore, which may have passed through a Schiff-base intermediate 
and undergone subsequent transformations to a stable compound or product.   
4.1.3 Covalent Binding of Fluorophore 
The next question addressed was whether the fluorophore was covalently or 
non-covalently bound to protein species of the protein component of the WSF.  
The concentrate of peaks A and B was denatured with urea, followed by eluting 
through the Sephadex G-75 column. 
There was no difference in the fluorescence elution profile of control and urea 
treated samples, as both eluted in the high MW region of Sephadex G-75 column 
(Fig 22).  These results indicate that the fluorophore is in fact covalently bound to 
the proteins.  This is due to fact that protein component of WSF was denatured 
with urea and if fluorophore was non-covalently bound to protein component then 
fluorescence elution profile should have shown appearance of fluorescence in 
the low MW region and not the high MW region of the Sephadex G-75 column.  
This agreed with the literature based on low molecular weight model compounds 
that the formed fluorophore(s) were covalently bound [23-26].  
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4.2 Characterization of the Protein Component of WSF 
Peak A eluted from the Sephadex G-75 column showed multiple protein bands 
with major bands at 80, 67, 51, and 30 kDa (Fig 23).  Peak B eluted from the 
Sephadex G-75 column showed three protein bands with major bands at 80, 68 
and 51 kDa (Fig 23).    Excitation and emission spectra of peaks A (Fig 18) and 
B (Fig 19) were similar to published spectra for aldehyde modified lysine 
derivatives [18, 21, 24, 31]. 
The next step was to determine if there was one or multiple species in the protein 
component that contained the fluorophore.  This would give insights if aldehyde 
modifications of proteins were indiscriminate or specific toward one species.  
4.2.1 Isolation of Major Proteins Present in the WSF Protein 
Component 
The major protein in peak B had a MW of 67 kDa.  The first predication was that 
this 67 kDa protein could be human serum albumin (HSA).  HSA is the major 
protein in human serum comprising 60% of the total protein composition and it 
has a MW of 68 kDa.  The 67 kDa protein was isolated by elution through 
Sephadex G-75 (Fig 24) and purity was monitored by SDS-PAGE gel.  SDS-
PAGE gels of concentrates of 67 kDa fractions showed that the 67 kDa protein 
was isolated and purified to >98% purity (Fig 25, insert). 
The next step was the protein identification of 67 kDa band.  This was performed 
by tryptic digestion of the isolated 67 kDa gel plug.  Tryptic fragments of digested 
67 kDa protein gel plug were analyzed using MALDI TOF 4700 Analyzer MS (Fig 
27).  Protein was identified by running a peptide mapping fingerprinting database 
search, which confirmed with 100% confidence interval that the 67 kDa band was 
HSA (Fig 27).  HSA was identified with a high protein score, which was a good 
parameter of protein identification using MS.  The MW matched of that 
determined from SDS-PAGE gels.  This confirmed our hypothesis that the 67 
kDa protein was HSA.  This also showed that HSA was the major and the most 
abundant species present in the protein component of WSF. 
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Emission spectra of the isolated HSA showed significant similarities to spectra 
published in the literature of in vitro modified proteins with aldehydes, showing an 
excitation maximum at 350 nm and emission maximum at 460 nm (Fig 25).  The 
emission spectrum of isolated HSA suggested that we were detecting the same 
fluorophore(s) that was reported in literature [23-26]. 
As we identified HSA as the major and most abundant species present in the 
protein component of WSF, the next question was: are there other protein 
species that contained fluorescence or was all the fluorescence residing on 
HSA?  HSA was also the most abundant protein in peak A.  In order to identify 
other species that may contain the fluorescence, the first step was to eliminate 
contaminated HSA from the rest of the protein species.  This was achieved by 
the use of Blue Sepharose CL-6B affinity column.  This column has a high 
capacity for absorbing HSA from mixtures of serum proteins to >95% removal.  A 
step gradient elution was used for elution of proteins and HSA as described in 
the experimental section.  The absorbance elution profile showed 2 peaks 
correlating with 2 fluorescence peaks (Fig 28).  The first peak eluting was the 
run-through peak (A*) that did not containing HSA.  The second peak, which is 
eluted at a high ionic strength, was the HSA.  SDS-PAGE gel of peak A* showed 
>98 % HSA removal (Fig 29).  The fluorescence elution profile suggested that 
there were other proteins apart from HSA that contained fluorescence, i.e., 
multiple proteins present in WSF contained fluorescent adducts within their 
structures.  It also showed that more than 50% of the fluorescence was present 
in peak A*.  This showed that there were multiple protein species that contained 
the fluorescence.  This also showed that the modification of protein species was 
at least somewhat indiscriminate and was not specific towards one protein. 
Peak A* contained three major proteins with MW 80, 51 and 30 kDA.  The goal 
was to isolated individual proteins from this mixture and monitor the fluorescence 
to give insights into what specific proteins contained the fluorophore.  The 80 kDa 
protein suggested that it could be human serum transferrin (HST).  HST is one of 
the more abundant serum proteins and has a MW of 80 kDa.  If the 80 kDa band 
could be confirmed to be HST, it would make isolation from other proteins easier 
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as there was a published procedure for purification of HST from other serum 
proteins [69].   
To confirm the presence of HST in peak A* from Blue Sepharose affinity column, 
a western blot experiment was conducted on concentrate of peak A*.  Western 
blot experiment was conducted by using anti-HST antibody as described in the 
experimental section.  Western blot experiment confirmed the presence of HST 
in peak A* for the 80 kDa band (Fig 30).   
To isolate HST from the other 2 protein species, DEAE Sepharose ion-exchange 
chromatography was used.  The literature had shown that this column is very 
effective on purifying HST from other serum proteins using a NaCl gradient.  
Concentrates of peak A* from Blue Sepharose affinity column were passed 
through a DEAE Sepharose column as described in the experimental section.  
The absorbance elution profile showed 2 peaks with correlating fluorescence 
peaks (Fig 31).  The run-through peak (peak A1) contained 2 protein bands (55 
and 30 kDa) as determined by SDS-PAGE gel (Fig 35).  HST was eluted in the 
second peak with a gradient of NaCl.  The fluorescence elution profile 
demonstrated that fluorescence was present in HST and peak A1.  The majority 
of fluorescence (64%) was present with HST.  SDS-PAGE had shown that >98 % 
pure isolated HST was obtained from DEAE Sepharose column (Fig 32, insert).  
Emission spectra of isolated HST (Fig 32) had shown similarity with isolated HSA 
emission spectrum, suggesting that the same fluorophore(s) may be present in 
both isolated proteins.  This was significant in that it showed that two of the most 
abundant proteins in serum were aldehyde modified.  Both proteins have 
important biological functions that, if altered, could result in biochemical or 
metabolic disorders.  
HST was further confirmed using MALDI TOF/MS as described in the 
experimental section.  HST gel plugs were trypsin digested followed by analysis 
by 4700 Proteomics Analyzer MS (Fig 33).  Peptide mapping fingerprinting 
database search confirmed with 100% C.I. that the protein was HST (Fig 34).  
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The protein score was high and the MW weight matched that of HST.  This 
agreed with our hypothesis that the 80 kDa protein was HST. 
 
HST and HSA proteins were the major protein species of WSF protein 
component that contained fluorescence.  This also showed that aldehyde 
targeted the most abundant proteins in the serum and caused modification that 
could have an effect on function.  In order to determine differences and make a 
comparison between the 2 isolated proteins, fluorescence units of both isolated 
proteins were calculated (as described in the experimental section) per mg of 
protein.  Isolated HSA had 23 fluorescence units/mg protein and isolated HST 
had 12 fluorescence units/mg protein.  This suggested that HSA had almost 
double the fluorescence units per amount of protein, and this would suggest that 
HSA had more fluorescent fluorophore within its structure than HST.  Both 
proteins had about 10% lysine amino acids within their amino acids sequences.  
We performed studies to identify possible lysine residues within HSA, and we 
were able to identify around 11 lysine pairs with close distances that could result 
in a fluorophore formation.  With HST, we were not able to perform such 
calculations, as there is no crystal structure for HST.  But this could suggest that 
HSA had more lysine pairs that could react with aldehyde to form the 
fluorophore(s) than HST, i.e., more fluorophores were present in HSA than HST.  
To identify the 2 protein species present in peak A1 from the DEAE Sepharose 
column, a MALDI TOF/MS experiment was conducted.  Gel plugs of the 2 protein 
bands were tryptic digested followed by analysis using MALDI TOF/MS.   The 
peptide mapping fingerprinting database search identified with 99% C.I. Ig-G 
protein for the 51 kDa (Figs 36, 37).  Ig-G is also one of the abundant proteins in 
serum.  The protein score was not as high as HSA and HST, and this could be 
due to the fact that the amount and concentration was low.  This is one of the 
major factors that influence the protein score. 
For the 30 kDa protein, the peptide mapping fingerprinting database searches 
identified carbonic anhydrase as the protein (Figs 38, 39).  The protein score 
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was very low and C.I. was 0%.  This could be attributed to the fact that carbonic 
anhydrase was in low abundance and this could influence the score and C.I. as 
mentioned earlier.  But the MW matched with  the predicted MW determined from 
SDS-PAGE gels. 
Fluorescence was present in both Ig-G and carbonic anhydrase and future work 
should focus on further separation of these proteins and determination if 
fluorescence would reside on one of them of both of them.  Ion-exchange 
chromatography could be a good separation technique for the separation.  But 
Ig-G or carbonic anhydrase or both of them are going to be minor species in the 
protein component of WSF as the bulk and the majority of fluorescence was 
present in HSA and HST. 
4.3 Characterizations Studies on HSA and HST 
The aim of these experiments was to digest isolated proteins into large peptide 
fragments and to detect fragments that contained fluorescence.  This would give 
us information if there were a single or multiple modification sites within the 
isolated proteins.  This would provide an insight for future work that should focus 
on modified fragments and try to digest them into smaller fragments and could 
determine exactly where the fluorophore (s) present in the amino acid sequence 
of proteins.  This subsequently would lead to determination of the chemical 
structure of the fluorophore. 
4.3.1 Characterization of Isolated HSA 
4.3.1.1 CNBr Digestion of Isolated HSA 
CNBr digestion of isolated HSA produced the expected seven fragments (Fig 43) 
[66].  The Ulrogel AcA gel filtration column was used for the separation of the 
CNBr peptide fragments.  The absorbance elution profile had shown four peaks, 
labeled peaks 1, 2, 3 and 4 according to elution order (Fig 44).  The fluorescence 
elution profile showed three peaks correlating with peaks 1, 3 and 4 absorbance 
peaks.  The fluorescence elution profile suggested there were multiple binding 
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sites of fluorophore within isolated HSA.  Peak 1 from the elution profile had the 
largest fluorescence intensity, and confirmed by SDS-PAGE that it was the 20 
kDa peptide fragments (Fig 45).  This agreed with our lysine residues study 
where 4 out of the 11 lysine pairs were identified to be present in the 20 kDa 
peptide fragment.  Peaks 3 and 4 suggested that there were composed of 
multiple peptide fragments bound together. 
To gain more understanding and knowledge of what peptide fragments were 
modified and contained the fluorophore (s), we used C18 reverse-phase HPLC.  
The literature showed that HSA CNBr peptide fragments could be resolved by 
HPLC using a C18 column, showing that five of the seven peptide fragments 
could be completely resolved [67, 68].  A fluorescence detector was added to the 
HPLC system so as to be able to monitor absorbance and fluorescence at the 
same time.  This would give accurate determination of what peptide fragments 
contained the fluorescence intensity.  The elution profile was comparable to one 
published in the literature (Fig 46) [67, 68].  The fluorescence elution profile 
showed multiple fragments containing fluorescence, suggesting also there were 
multiple binding sites of fluorophore (Fig 47).  The 20 kDa peptide fragment 
showed also the highest fluorescence intensity. 
Combining both elution profiles from the AcA column and HPLC, we predict that 
there are at least 4 binding sites within HSA.  The peptides fragments that 
seemed to contain the fluorophore were the 20, 9.5, 4.0 and 3.4 kDa peptide 
fragments.  From our lysine pairs study, it showed that the 20 had 4 lysine pairs, 
the 9.5 had 3 lysine pairs, the 4.0 had 2 lysine pairs, and 3.4 had 2 lysine pairs 
(Table 3).  Future work should focus on isolating these peptide fragments and 
perform MALDI TOF/MS experiments coupled with trypsin digestion, to exactly 
locate the position of the fluorophore in the amino acid sequence. 
4.3.1.2 Isoelectric Focusing Experiments 
The main aim of these experiments was to detect if shifts in pI shift due to in vitro 
aldehyde modification of HSA.  Our hypothesis was that if there was significant 
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lysine residues modification by aldehydes, then loss of those lysine residues 
should have an effect on pI shifting HSA’s pI towards the acidic side.  The IEF of 
control HSA displayed the expected five isoforms of HSA (Fig 51).  The IEF of 
hex (Fig 52) and 4-ONE (Fig 53) modified HSA didn’t display clearly the isoforms 
of HSA.  But there were significant pI shift for both modified samples, but 4-ONE 
sample showed more shift towards the acidic side.  This could be true for 4-ONE 
as it is predicated to be a more reactive aldehyde than hex.  Approximation of the 
pI for hex modified HSA was 5.50 and for 4-ONE was 5.32 as compared to HSA 
pI of 5.62.  The reason of not clearly visualizing the isoforms for both modified 
samples could be that the aldehyde modification resulted in crosslinking of some 
isoforms together.  Future experiments should focus on performing MALDI 
experiments on these isoforms and determine changes in MW as compared to a 
control sample. 
4.3.2 Characterizations of Isolated HST 
4.3.2.1 CNBr Digestion of Isolated HST 
Isolated HST was digested with CNBr producing the expected three fragments 
[69].  One fragment had four peptide fragments bound together by disulfide 
bonds with MWs ranging from 7-27 kDa.  The second fragment had two peptides 
bound together by disulfide bonds with MW 3 and 9 kDa.  The third fragment 
contained one peptide of MW 5.8 kDa. 
Separations of peptide fragments were achieved by elution through the P-10 
filtration column.  The absorbance elution profile detected 3 peaks corresponding 
to the three fragments described above, labeled peaks A, B and C according to 
order of elution (Fig 54).  The fluorescence elution profile showed only one peak 
correlating with absorbance peak A.  This suggested that there could be one or 
multiple binding sites of fluorophore, as peak A was composed of 4 peptide 
fragments joined by disulfide bonds.  SDS-PAGE image of peak A showed the 
expected four peptide fragments (Fig 55).  
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In order to determine if the fluorescence resided on one or multiple peptide 
fragments in peak A, we needed to reduce the disulfide bonds and separated the 
peptide fragments. Concentrated fractions of peak A from the P-10 column were 
reduced and carboxyamidomethylated and then eluted through the P-10 column.  
The absorbance elution profile showed three peaks, labeled peaks 1, and 2 
according to the elution order (Fig 56).  Peak 1 was composed of peptide 
fragments 27 and 15 kDa and peak 2 was composed of peptide fragments 8 and 
7 kDa.  The fluorescence elution profile showed two peaks corresponding with 
the two absorbance peaks (Fig 56).  The fluorescence elution profile showed that 
there were multiple binding sites of fluorophore within isolated HST.  The levels 
of fluorescence intensities were comparable in the 2 peaks.  Future work should 
focus on separating these fragments through the use of another gel filtration 
column or ion-exchange column, and determine what peptide fragments 
contained the fluorescence.  This could lay the work for future MALDI 
experiments to elucidate the exact position and MW of the fluorophore. 
4.4 In Vitro MALDI Experiments on HSA and HST 
Pollack’s work in our lab had demonstrated that HSA incubation in vitro with 
aldehyde resulted in fluorescence development over the time of the incubation 
[71].  The fluorescence reached its maximum after 48 h, where it reached a 
plateau.    If there was fluorophore formation resulting from covalent adducts, 
then we should detect a significant shift in MW using MALDI TOF/MS.  HSA 
(Figs 48-50) and apo-HST (Figs 58-60) were incubated with aldehydes and were 
analyzed by MALDI TOF/MS.  For both proteins, significant MW increases were 
detected with both aldehydes.  These confirmed our hypothesis that aldehyde 
modification resulted in an increase in MW due to fluorophore formation. 
We estimated the number of aldehyde molecules that could be reacting based on 
the MW difference between the control and modified sample.  With 4-ONE 
modified samples of HSA and HST, there were about comparable number of 
molecules reacting (19 for HSA and 12 for HST).  As for the hex modified 
samples of HSA and HST, identical numbers of molecules were calculated (34 
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for HSA and 35 for HST).  These results were not what we expect based on the 
fact that 4-ONE was apparently more reactive as compared to hex.  One 
explanation could be that 4-ONE and hex generate different types of 
fluorophores with different quantum yields.  One useful future experiment is to 
use HNE and 2-octenal and compare all the data and determine if a pattern 
develops or not.    
4.5 In Vitro Fluorescence Development Studies on HST 
In vitro experiments were conducted on apo and diferric forms HST incubated 
with aldehydes such as hex and 4-ONE.  The main aim was to determine if there 
will be protein fluorescence development with time as result of aldehyde 
modification.  This was based on work done by Pollack in our lab where she 
determined that there was fluorescence development over time in HSA due to 
aldehyde modification [71].  Fluorescence units time points of hex (Fig 61) and 4-
ONE (Fig 62) modified HST showed an increase in fluorescence in both apo and 
diferric forms of HST.  There was a larger fluorescence increase in the apo form 
as compared with the diferric form with both aldehydes.  This could be due to the 
diferric form being in a more closed structural conformation and lysine residues 
may not be surface accessible to react with aldehydes.  For the apo form, it is 
more of an open structural conformation of the protein, where the lysine residues 
could be more accessible and can react readily with aldehydes.  4-ONE showed 
a 3-fold fluoresence increase for both apo and diferric forms compared to the hex 
sample. 
The second aim of these experiments was to detect if there will be dimers or 
trimers formation with time as a result of incubation of apo HST with aldehydes.  
Samples were taken at different time points and were run on SDS-PAGE gel to 
detect changes.  SDS-PAGE gels had showed that there was indeed dimer  and 
possibly trimer formations of crosslinked HST as a result of incubation of apo 
HST with both hex and 4-ONE aldehydes.  This was significant because it 
demonstrated that protein crosslinking (inter or intra) existed as a result of 
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aldehyde modification that resulted in the formation of dimers and possibly 
trimers. 
4.6 In Vitro Functional Studies on HST 
4.6.1 Iron Uptake by Apo HST 
The aim of these experiments was to address the following question:  does 
aldehyde modification of apo HST have an effect on the affinity or binding 
capacity for iron?  Apo-HST was aldehyde-modified (hex and 4-ONE), followed 
by Fe titration, monitoring absorbance at 465 nm as described in the 
experimental section.  Absorbance changes at 465 nm were used to measure Fe 
binding by apo-HST.  Both hex and 4-ONE iron uptake plots demonstrated 
almost a 50% decrease in absorbance per mg protein compared to the control 
unmodified sample.  The control unmodified apo-HST showed an equivalence 
point of about 2, illustrating the two Fe binding sites of apo-HST.  For the hex 
(Fig 64) and 4-ONE (Fig 65) modified apo-HST, there was a decrease of the 
equivalence point to 0.73 and 1.13 respectively.  This suggested that there might 
be a loss of an Fe binding site due to aldehyde modification or the binding 
capacity of apo-HST was decrease by 50% for both binding sites.  This led to the 
next question that we needed to address: which of the two sites has lost it 
binding as a result of aldehyde modification, or are both sites affected equally in 
loss of their binding capabilities?   
If there was a discriminating loss of one of the two sites, we postulated it might 
be the N-site.  This hypothesis was based on fact that the N-site functions by 
what is termed as the “dilysine trigger” (as mentioned previously in Chapter 1) 
[58, 59].  Two lysines within a close proximity and are responsible for the binding 
of an iron.  If one or both of these lysines became modified with aldehydes, then 
apo-HST would be expected to lose Fe binding capability at the N-site.  This 
would subsequently affect the kinetics of release of iron from HST as the release 
of Fe would be mainly attributed to the C-site.  Experimentally, in order to prove 
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the N-site hypothesis, we had to perform experiments monitoring kinetics of iron 
release from aldehyde modified versus unmodified diferric HST. 
4.6.2 Fe Kinetics of Release from HST 
Experiments were conducted to measure the Fe kinetics of release from HST as 
described in the experimental section.  Commercial diferric-HST experiments 
optimized the experimental conditions and the calculated rate constants of both 
sites were comparable with literature values [61].  Then commercial diferric-HST 
was modified with hex to observe changes in rate constants due to aldehyde 
modification.  At pH 7.4, there were no changes in the rate constants between 
the control and hex modified diferric HST for both the N-and the C-sites.  This 
could be due to the fact that the diferric HST was already in the closed 
conformation and both irons were bound, so modification didn’t have an effect as 
the susceptible (lysines) residues were buried or had diminished nucleophilicity 
due to binding to other amino acid residues.  At pH 5.6, there was a decrease in 
the rate constants of the C-site compared to the control sample.  This suggested 
that aldehyde modification had an effect on kinetics of release of Fe from C-site.  
This agreed with the fluorescence development experiments where we detected 
fluorescence development over time of diferric HST when incubated with the 
aldehydes.  It showed that there was fluorophore formation and this could have 
an effect on the kinetics of release in this experiment. 
4.6.2.1 Saturation and Titration Experiments 
To prove our previous hypothesis that the N-site binding capability was lost due 
to aldehyde modification, saturation and titration experiments were performed on 
aldehyde-modified apo-HST followed by monitoring of Fe kinetics of release.  
Apo-HST was modified with hex and 4-ONE followed by either saturation or 
titration experiments.  Both the saturation and the titration experiments were 
conducted on control unmodified and aldehyde-modified apo-HST, followed by 
measurements of the kinetics of Fe release to calculate the rate constants of 
both binding sites.  Two different methods of binding iron to control and 
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aldehyde-modified apo-HST were used so as to obtain more reliable data as both 
methods should yield similar or comparable results. 
For the data analysis, our main focus would be on pH 7.4 kinetics and rate 
constants as at pH 5.6 the N-site rate constant cannot be calculated accurately 
as it is too fast to measure with the available instrument as mentioned previously.  
Plots of control saturated and titrated apo-HST displayed biphasic kinetics due to 
the release of Fe from both sites.  If our hypothesis was correct or valid, then for 
the aldehyde-modified saturated or titrated apo-HST we should observe 
predominantly monophasic kinetics due to the loss of one of the binding sites.   
Data and plots of kinetics runs of aldehyde-modified (hex and 4-ONE) saturated 
and titrated apo-HST at pH 7.4 had shown different kinetic patterns as compared 
to control.  There was the disappearance of the biphasic kinetics as detected with 
the control and the appearance of monophasic kinetics.  The calculated rate 
constants were comparable to the values of the C-site calculated for the control 
unmodified sample.  There were decreases in the rate constants detected for the 
C-site in the titration experiments data for both the hex and 4-ONE, as opposed 
to the saturation experiments where the rate constants for the control and 
aldehyde modified samples were comparable.  
On the other hand, data from both the saturation and the titration experiments 
suggested that there was the loss of the N-site due to aldehyde modification at 
pH 7.4.  These data suggested that our hypothesis was correct and valid that the 
binding site lost to aldehyde modification was the N-site.  This also suggested 
that the 2 lysine residues that act as the “dilysine trigger” for Fe release and 
binding were somehow being aldehyde modified and this resulted on the loss of 
the binding capability at the N-site. 
At pH 5.6, there was a drastic decrease in the rate constants for the C-site 
between the control unmodified and the 4-ONE modified HST for the saturation 
experiments.  The kinetic time course also was very noisy and this could have an 
effect on the rate constants calculations, and it was reproducible on all kinetic 
measurements.  But it could also mean that 4-ONE modification had an effect on 
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the kinetics of release from the C-site.  This was not noticeable with the hex 
modified sample as the rate constants for the control and hex modified samples 
were comparable.   This was also detected in the titration experiments where the 
hex modified samples didn’t show decrease in the rate constants for the C-site, 
but the 4-ONE modified samples showed decrease.  Comparing both the 
saturation and the titration experiment data for the 4-ONE, it suggested that 4-
ONE had also an effect on the kinetics of Fe release from the C-site at pH 5.6. 
The saturation and the titration experiments results were comparable on showing 
the loss of N-site binding site at pH 7.4.  This could be significant as this may 
cause the development of chronic iron disorder as a result of the loss of the N-
site binding capability.  There were differences concerning the C-site rate 
constants as the titration experiments showed that there were also decreases in 
the rate constants of the C-site at both pHs.  This could also be valid as 4-ONE is 
a very reactive aldehyde and could also induced modifications in the C-site that 
could affect the kinetics of Fe release.  A future experiment to try to better 
understand the extent of modification of C-site, would be to use HNE and octenal 
as modifying aldehydes and determine from the data obtained from all these four 
aldehydes experiments the effect of modification of the C-site.  On the other 
hand, to reinforce our hypothesis there was a loss of N-site Fe binding 
capabilities due to aldehyde modification, future experiments should focus on the 
use of stopped flow experiments to be used at pH 5.6, to corroborate loss of N-
site binding capability at pH 5.6. 
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4.7 Serum Incubation Experiments 
The main aim of these experiments was to modify whole serum with aldehydes 
and determine changes if any to the fluorescence properties of peaks A and B, 
and if there would be dimers or trimers formations as a result of aldehyde 
modification.  The elution profiles showed a large increase in fluorescence 
intensities of peaks A and B as compared with control with both aldehydes (hex 
and 4-ONE), with 4-ONE showing larger increase in fluorescence intensity than 
hex.  4-ONE modified sample showed a 24-fold fluorescence increase and the 
hex modified sample showed a 3-fold fluorescence increase, of peaks A and B 
compared to their respective control samples.  This suggests that modifying 
whole serum may result in a large number of random cross-linking reactions, 
resulting in an increase in the number of fluorophore generated. 
An SDS-PAGE gel (Fig 85) of hex incubated serum had shown that there was 
indeed formation of dimers and possibly trimers of HSA due to either intra or inter 
crosslinking of proteins as a result of aldehyde modification.  The cross links 
were detected only in peak A and was absent from peak B.  Future experiments 
should focus on the identifications of the proteins that were crosslinking and this 
could be done by MALDI TOF experiments where gel plugs of the crosslinks 
could be analyzed to identify the proteins involved in crosslinking. 
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4.8 Subject Study 
This was a pilot study where the main aim of the experiment was to observe if 
there are variations between different elderly subjects on peaks A and B 
fluorescence properties.  This could give insights to if these WSFs were the 
same in all subjects or if there were major differences in component peaks.  The 
study was conducted on serum samples from six different aging subjects.  The 
elution profiles from the Sephadex G-75 were fitted using Origin software where 
peaks areas percentages of peaks A and B were calculated, as described in the 
experimental section.  Data showed that there were indeed significant variations 
between subjects on peaks A and B fluorescence composition (Fig 88).  For 
example, subject 1 had 60% peak A and 40% peak B, while subject 6 had 25% 
peak A and 75% peak B.  This showed that within aged subjects there were 
major differences between peaks A and B.  Future experiments may include 
performing a study of younger subjects and compare them with old age subjects, 
and determine if age correlates with peaks A and B fluorescence properties.  
Another experiment may include subjects at the different disease stages as 
compared to control samples.  This also raises the question of the origin of these 
pattern differences and whether changes in A:B ratio reflect or correlate with 
specific disease states of oxidative stress status. 
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4.9 Is WSF a Reflection of In Vivo LP? 
Experiments conducted on this dissertation agreed with the conclusion that WSF 
was a reflection of in vivo LP.  The WSF components showed similar 
fluorescence properties as in vitro reactions fluorescence properties conducted 
on proteins and amino acid analogues.  The fluorescence properties determined 
on isolated HSA and HST agreed with the literature fluorescence properties of in 
vitro aldehyde modified proteins.  We did identify at least two major and 
abundant proteins that are present in high protein amounts and are more 
susceptible to aldehyde modification than other less abundant proteins.  This 
could be significant because WSF presence in these major serum proteins could 
be used as a biomarker for LP associated diseases.   
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